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INTRODUCTION 
As a result of the modern ‘high throughput’ approach to drug discovery, it has been estimated 
that up to 70% of the new chemical entities(NCEs) entering drug development possess 
insufficient aqueous solubility to allow adequate and consistent gastrointestinal (GI) absorption 
to ensure efficacy. 
           Molecules with poor solubility, often referred to as BCS Class II (poor solubility) or BCS 
Class IV (poor solubility and permeability), are typically impeded by poor and variable 
bioavailability. Higher drug doses can be used to compensate; however, this strategy can lead to 
side effects, food effects and inter subject variability. Consequently, a more sophisticated 
solution is required to assure the compound can be successfully developed.    
Drug Product Design to Overcome Solubility Issues 
        The options available to the development team to address solubility problems fall into two 
broad categories: 
                *API modifications 
               *Formulation technology. 
API modifications: 
       Potential API modifications include salt selection and polymorphism studies and cover 
particle-engineering approaches such as nanotechnology. These approaches seek to improve 
solubility through reducing the crystallinity within drug particles and increasing surface area. 
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Formulation technology: 
  Formulation technologies include amorphous solid dispersions and liquid systems, such 
as lipid and surfactant systems. These aim to enhance solubility through an improvement in 
intrinsic dissolution rate or by modifying the local environment around the dosage form. 
      SOLID DISPERSION TECHNOLOGY   
 The successful formulation of poorly water-soluble drugs is one of the major problems for 
pharmaceutical scientist. Over the years, a variety of solubilization techniques have been studied 
to improve the dissolution rate. To obtain more rapid and complete absorption such as using 
surfactant, hydro tropes and co-solvents, preparing co-precipitate, liquisolid compacts fast 
releasing microparticles interactive mixtures and number of researches had been carried to 
increase the solubility of poorly soluble drugs.
1 
Solid dispersion is one of the significant and widely used methods for solubility enhancement. 
Solid Dispersion technology has been successfully used to increase the dissolution rate and 
bioavailability of poorly water soluble drugs. Recently attempts are being made to incorporate 
porous materials in solids dispersion to increase to solubility. It has been widely used to improve 
the dissolution rate, solubility and oral absorption of poorly water-soluble drugs.2 
There are practical limitationsof these techniques. The salt formation is not feasible for neutral 
compounds and the synthesis of appropriate saltforms of drugs that are weakly acidic or weakly 
basic may often not be practical. Even when salts can be prepared, an increased dissolution rate 
in the gastrointestinal tract may not be achieved in many cases because of the reconversion of 
salts into aggregates of their respective acid or base forms. The solubilization of drugs in organic 
solvents or in aqueous media by the use of surfactants and co-solventsleads to liquid 
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formulations that are usually undesirable from the viewpoints of patient acceptability and 
commercialization. Although particle size reduction is commonly used to increase dissolution 
rate, there is a practical limit to how much size reduction can be achieved by such commonly 
used methods as controlled crystallization, grinding, etc. 
the use of very fine powders in a dosage form may also be problematic because of handling 
difficulties and poor wettability.3 
Polymers used in solid dispersions 
    Various Suitable water-soluble carriers include polymers such as polyethylene glycol, 
poloxamers, polyoxyethylenestearates, poly-epsilon-caprolactone, polyvinylpyrrolidone (PVP), 
polyvinylpyrrolidone-polyvinyl acetatecopolymer PVP-PVA (Kollidon VA64), poly-meth 
acrylic polymers (Eudragit RS, Eudragit RL, Eudragit NE, Eudragit E) and polyvinyl alcohol 
(PVA), hydroxypropylcellulose (HPC), hydroxypropylmethyl cellulose (HPMC), methyl 
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cellulose, and poly ethylene oxide (PEO). Further various molecular weight grades of these 
polymers have been used for the preparation of solid dispersion and solid solutions. Polymers 
and surface-active agent combinations are used. Superdisintegrants and Cyclo-dextrins are 
primarily used to enhance solubility, chemical protection, test masking and improved handling 
by the conversion of liquids into solids by entrapment. 
       Polymers containing acidic functional groups may be suitable for solid dispersions, which 
release the active substance in a preferred pH range providing acceptable absorption in the 
intestines. Such polymers may be one or more selected from the group comprising 
hydroxypropyl methylcellulose phthalate (HPMCAP), polyvinyl acetate phthalate (PVAP), and 
Hydroxypropyl methyl cellulose acetate succinate (HPMCAS), Alginates, Carbomers, 
carboxymethyl cellulose. 
The weight ratio of active substance to polymer may be in a range from about 3: 1 to about 1: 20. 
However, narrow ranges of form about3: 1 to about 1: 5, such as, e.g., from about 1: 1 to about 1: 
3 or above may also be used.4 
SELECTION OF CARRIER(S) 
The properties of the carrier have a profound influence on the dissolution characteristics 
of the dispersed   drug. A carrier ought to meet the following prerequisites for being suitable for 
increasing the dissolution rate of a drug 49 
It should be 
 Freely water soluble with rapid dissolution properties 
 Nontoxic and pharmacologically inert 
 Heat stable with a low melting point for the melt method 
 Soluble in a variety of solvents 
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 Preferably enhancing the aqueous solubility of the drug 
 Chemically compatible with the drug 
 Forming only weakly bounded complex with the drug16 
 Characteristics of Ideal polymer system 
1.It should be chemically inert and free from leachable impurities. 
2. It should be non toxic and compatible with the environment. 
3. It should have good mechanical strength. 
4. It should be easy and inexpensive to fabricate.  
5. It should be easily sterilized. 
6. It should demonstrate acceptable shelf life.
5.6 
Drug release mechanisms for polymeric drug delivery. 
 Two broad categories of polymer systems have been studied. The reservoir device 
involves the encapsulation of a drug within a polymer shell,while the matrix device describes a 
system in which a drug is physically entrapped with in a polymer network.7 
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Fig: 1.2possible drug release mechanisms for polymeric drug delivery 
 
As shown in above figure the drug will be released over time either by diffusion out of the 
polymeric matrix or by erosion (due to degradation) of the polymer or by combination of two 
mechanisms.Reviews mathematicalaspectsof release of drug from polymer matericics.8 
ADVANTAGES OF SOLID DISPERSIONS: 
Generally, solid dispersion is mainly used 
1. To reduced particle size.  
2. To improve wet ability. 
3. To improve porosity of drug. 
4. To decrease the crystalline structure of drug in to amorphous form. 
5. To improve dissolvability in water of a poorly water-soluble drug in a pharmaceutical.  
6. To mask the taste of the drug substance. 
AKCP DEPARTMENT OF PHARMACEUTICS  Page | 7 
 
7. To prepare rapid disintegration oral tablets. 
8. To obtain a homogenous distribution of small amount of drugs at solid state. 
9. To stabilize unstable drugs. 
10. To dispense liquid or gaseous compounds. 
11. To formulate a faster release priming dose in a sustained release dosage form. 
12. To formulate sustained release dosage or prolonged release regimens of soluble drugs using 
poorly soluble or insoluble carriers. 
1. Particles with reduced particle size 
Molecular dispersions, as solid dispersions, represent the last state on particle size 
reduction, and after carrier dissolution the drug is molecularly dispersed in the dissolution 
medium. Solid dispersions apply this principle to drug release by creating a mixture of a poorly 
water soluble drug and highly soluble carriers. A high surface area is formed, resulting in an 
increased dissolution rate and, consequently, improved bioavailability9. 
2. Particles with improved wet ability 
A strong contribution to the enhancement of drug solubility is related to the drug wet 
ability improvement verified in solid dispersions
11
. It was observed that even carriers without 
any surface activity, such as urea improved drug wetability. Carrierswith surface activity, such as 
choliacid and bile salts.When used, can significantly increase the wet ability property of drug. 
Moreover, carriers can influence the drug dissolution profile by direct dissolution or co-solvent 
effects
10
. 
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3. Particles with higher porosity 
Particles in solid dispersions have been found to have a higher degree of porosity
12
. The 
increase in porosity also depends on the carrier properties; for instance, solid dispersions 
containing linear polymers produce larger and more porous particles than those containing 
reticular polymers and, therefore, result in a higher dissolution rate
13
. The increased porosity of 
solid dispersion particles also hastens the drug release profile. 
4. Drugs in amorphous state 
Poorly water soluble crystalline drugs, when in the amorphous state tend to have higher 
solubility14. The enhancement of drug release can usually be achieved using the drug in its 
amorphous state, because no energy is required to break up the crystal lattice during the 
dissolution process 15. In solid dispersions, drugs are presented as supersaturated solutions after 
system dissolution, and it is speculated that, if drugs precipitate, it i s as a Metastable 
polymorphic form with higher solubility than the most stable crystal form9. For drugs with low 
crystal energy (low melting temperature or heat of fusion), the amorphous composition is 
primarily dictated by the difference in melting temperature between drug and carrier. For drugs 
with high crystal energy, higher amorphous compositions can be obtained by choosing carriers, 
which exhibit specific interactions with them
15
. 
5. Rapid disintegration of oral tablets 
Drug is formulated with hydrophilic carrier (e.g. PEG) as a solid dispersion to increase its 
aqueous solubility anddissolution. Then superdisintegrant (e.g. croscarmellose sodium) is used in 
tablet formulation to achieve rapid disintegration of tablets prepared by wet granulation method. 
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These rapidly disintegrating tablets can be used as an alternative to parenteral therapy enabling 
patient for self-medication even without the aid of water. 
DISADVANTAGES OF SOLID DISPERSIONS: 
Serajuddin (1999) identified some problems limiting the commercial application of solid 
dispersion which involved (a) its method of preparation, (b) reproducibility of its 
physicochemical properties, (c) its formulation into dosage forms, (d) the scale up of 
manufacturing processes, and (e) the physical and chemical stability of drug and vehicle. Solid 
dispersions are not broadly used in commercial products due to mainly the problem of 
crystallization of the components from amorphous state during processing (mechanical stress) or 
storage (temperature and humidity stress). Moisture may increase drug mobility and promote 
drug crystallization and thus may hamper storage stability of amorphous pharmaceuticals .Phase 
separation, crystal growth or conversion of a product to more stable structure from metastable 
crystalline form during storage are also considered to be major hurdles to commercialize solid 
Dispersions as they result in decreased solubility and thus dissolution rate16.  
LIMITATIONS OF SOLID DISPERSIONS 
Although a great research interest in solid dispersion in the past four decades, the 
commercial utilization is very limited. Problems of solid dispersion involve (i) the physical and 
chemical stability of drugs and vehicles, (ii) method of preparation, (iii) reproducibility of its 
physicochemical properties, (iv)formulation of solid dispersion into dosage forms, and(v) scale-
up of manufacturing processes 
17
. 
CLASIFICACTION OF SOLID DISPERSION SYSTEMS 
It is appropriate to classify various systems of solid dispersion on the basis of their major 
fast release mechanisms. Chiou and Riegelman classified solid dispersion into the following six 
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representative types: Simple eutectic mixtures, solid solutions, glass solution and glass 
suspensions, amorphous precipitations in a crystalline carrier, compound or complex formation, 
and combinations of the previous five types. 
CATEGORIES OFSOLID DISPERSIONS 
a. Simple eutectic mixtures 
b.  solid solutions  
i)According to their miscibility 
ii) According to the way in which the solvate molecules are distributed in the solvendum    
i) According to their miscibility  
 Continuous 
 Discontinuous solid solutions. 
ii) According to the way in which the solvate molecules are distributed in the solvendum 
 Substitutional crystalline solid solutions. 
 Interstitial crystalline solid solutions. 
 Amorphous solid solutions.  
c. Glass solution 
d. amorphous precipitations in a crystalline carrier 
 
AKCP DEPARTMENT OF PHARMACEUTICS  Page | 11 
 
 
Simple eutectic mixtures 
Simultaneously, whereas when other compositions are cooled, one of the components 
starts to crystallize out before the other. Solid eutectic mixtures are usually prepared by rapid 
cooling of a co melt of the two compounds in order to obtain a physical mixture of very fine 
crystals of the two components. When a mixture with composition E, consisting of a slightly 
soluble drug and an inert, highly water soluble carrier, is dissolved in an aqueous medium, the 
carrier will dissolve rapidly, releasing very fine crystals of When a mixture of A and B with 
composition E is cooled, A and B crystallize out the drug 
18,19
. The large surface area of the 
resulting suspension should result in an enhanced dissolution rate and thereby improved 
bioavailability. 
 
Fig:1.3 Phase diagram for a eutectic system 
Solid solutions 
Continuous solid solutions: 
In a continuous solid solution, the components are miscible in all proportions. 
Theoretically, this means that the bonding strength between the two components is stronger than 
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the bonding strength between the molecules of each of the individual components. Solid 
solutions of this type have not been reported in the pharmaceutical literature to date. 
Discontinuous solid solutions: 
In the case of discontinuous solid solutions, the solubility of each of the components in 
the other component is limited. A typical phase diagram is shown in Fig. 1.4.   Show the regions 
of true solid solutions. In these regions, one of the solid components is completely dissolved in 
the other solid component. Note that below a certain temperature, the mutual solubility’s of the 
two components start to decrease. Due to practical considerations it has been suggested by 
Goldberg 20 that the term `solid solution' should only be applied when the mutual solubility of 
the two components exceeds 5%. Whether or not a given solid solution can be utilized as a 
dosage form strategy will depend not only on the mutual solubility of the two components but 
also on the dose of the drug component. The upper limit for the mass of a tablet or capsule is 
about 1 g. Assuming that the solubility of the drug in the carrier is 5%, doses of above 50 mg 
would not be feasible with this strategy. Obviously, if the drug solubility in the carrier is 
significantly higher than 5%, larger doses can be entertained. 
 
Fig:1.4 Phase diagram for a discontinuous solid solution 
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Substitutional crystalline, interstitial crystalline and amorphous solid solutions 
Substitutional crystalline solid solutions: 
Classical solid solutions have a crystalline structure, in which the solute molecules can 
either substitute for solvent molecules in the crystal lattice or into the interstices between the 
solvent molecules. A substitutional crystalline solid dispersion is depicted in Fig. 1.5. 
Substitution is only possible when the size of the solute molecules differs by less than 15% or so 
from that of the solvent molecules 
21
. 
 
Fig:1.5Substitutional crystalline solid solution 
Interstitial crystalline solid solutions 
In interstitial solid solutions, the dissolved molecules occupy the interstitial spaces between the 
solvent molecules in the crystal lattice (Figs. 1.6). As in the case of substitutional crystalline 
solid solutions, the relative molecular size is a crucial criterion for classifying the solid solution 
type. In the case of interstitial crystalline solid solutions, the solute molecules should have a 
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molecular diameter that is no greater than 0.59 of the solvent molecule's molecular diameter
22
. 
Furthermore, the volume of the solute molecules should be less than 20% of the solvent. 
 
Fig:1.6 interstitial crystalline solid solution 
Amorphous solid solutions: 
  In an amorphous solid solution, the solute molecules are dispersed molecularly but 
irregularly within the amorphous solvent (Fig.1.7) Using griseofulvin in citric acid, Chiou and 
Riegelman23were the first to report the formation of an amorphous solid solution to improve a 
drug's dissolution properties. Other carriers that were used in early studies included urea and 
sugars such as sucrose, dextrose and galactose. More recently, organic polymers such as 
polyvinylpyrrolidone (PVP), polyethylene glycol (PEG) and various cellulose derivatives have 
been utilized for this purpose. Polymer carriers are particularly likely to form amorphous solid 
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solutions as the polymer itself is often present in the form of an amorphous polymer chain 
network. In addition, the solute molecules may serve to plasticize the polymer, leading to a 
reduction in its glass transition temperature. 
 
Fig:1.7: amorphous solid solution 
Glass solutions and glass suspensions: 
Chiou and Riegelman first introduced the concept of formation of a glass solution as 
another potential modification of dosage forms in increasing drug dissolution and absorption. A 
glass solution is a homogenous, glassy system in which a solute dissolves in a glassy solvent. 
The familiar term glass however, can be used to describe either a pure chemical or a mixture of 
chemicals in a glassy or vitreous state. The glassy or vitreous state is usually obtained by an 
abrupt quenching of the melt. It is characterized by transparency and brittleness below the glass 
transition temperatureEg. On heating, it softens progressively and continuously without a sharp 
melting point. 22 
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METHODS OF PREPERATION OF SOLID DISPERSIONS. 
Melting method:
 24
 
The melting or fusion method, first proposed by Sekiguchi and Obi involves the 
preparation of physical mixture of a drug and a water-soluble carrier and heating it directly until 
it melted. The melted mixture is then solidified rapidly in an ice-bath under vigorous stirring. 
The final solid mass is crushed, pulverized and sieved. Appropriately this has undergone many 
modifications in pouring the homogenous melt in the form of a thin layer onto a ferrite plate or a 
stainless steel plate and cooled by flowing air or water on the opposite side of the plate. In 
addition, a super-saturation of a solute or drug in a system can often be obtained by quenching 
the melt rapidly from a high temperature. Under such conditions, the solute molecule is arrested 
in the solvent matrix by the instantaneous solidification process. The quenching technique gives 
a much finer dispersion of crystallites when used for simple eutectic mixtures. However many 
substances, either drugs or carriers, may decompose during the fusion process which employs 
high temperature. It may also cause evaporation of volatile drug or volatile carrier during the 
fusion process at high temperature. Some of the means to overcome these problems could be 
heating the physical mixture in a sealed container or melting it under vacuum or in presence of 
inert gas like nitrogen to prevent oxidative degradation of drug or carrier 
Solvent method:
25
 
In this method, the physical mixture of the drug and carrier is dissolved in a common 
solvent, which is evaporated until a clear, solvent free film is left. The film is further dried to 
constant weight. The main advantage of the solvent method is thermal decomposition of drugs or 
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carriers can be prevented because of the relatively low temperatures required for the evaporation 
of organic solvents.    
However, some disadvantages are associated with this method such as  
1) The higher cost of preparation.  
2) The difficulty in completely removing liquid solvent.  
3) The possible adverse effect of traces of the solvent on the chemical stability           
4) The selection of a common volatile solvent.  
5) The difficulty of reproducing crystal form.  
6) In addition, a super saturation of the solute in the solid system cannot be attained   except in a 
system showing highly viscous properties 
Melting solvent method (melt evaporation):
24
 
It involves preparation of solid dispersions by dissolving the drug in a suitable liquid 
solvent and then incorporating the solution directly into the melt of polyethylene glycol, which is 
then evaporated until a clear, solvent free film is left. The film is further dried to constant weight. 
The 5 –10% (w/w) of liquid compounds can be incorporated into polyethylene glycol6000 
without significant loss of its solid property. It is possible that the selected solvent or dissolved 
drug may not be miscible with the melt of the polyethylene glycol. Also the liquid solvent used 
may affect the polymorphic form of the drug, which precipitates as the solid dispersion. This 
technique possesses unique advantages of both the fusion and solvent evaporation methods. 
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From a practical standpoint, it is only limited to drugs with a low therapeutic dose e.g. below 50 
mg.  
Melt extrusion method 
[26],[27], and [28]
 
The drug/carrier mix is typically processed with a twin-screw extruder. The drug/carrier 
mix is simultaneously melted, homogenized and then extruded and shaped as tablets, granules, 
pellets, sheets, sticks or powder. The intermediates can then be further processed into 
conventional tablets. An important advantage of the hot melt extrusion method is that the 
drug/carrier mix is only subjected to an elevated temperature for about 1 min, which enables 
drugs that are somewhat thermo labile to be processed. Solid dispersion by this method is 
composed of   active ingredient and carrier, and prepare by hot-stage extrusion using a co-
rotating twin-screw extruder. The concentration of drug in the dispersions is always 40% (w/w). 
The screw-configuration consist of two mixing zones and three transport zones distribute over 
the entire barrel length, the feeding rate is fix at 1 kg/h and the screw rate is set at 300 rpm. The 
five temperature zones are set at 100, 130, 170, 180, and 185
0
C from feeder to die. The extradites 
are collect after cooling at ambient temperature on a conveyer belt. Samples are milled for 1 min 
with a laboratory-cutting mill   and sieve to exclude particles >355µm.  
 
Fig:1.8Screw and kneading elements 
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Fig:1.9 Extrusion screw geometry 
Lyophilisation Technique 
Freeze-drying involves transfer of heat and mass to and from the product under 
preparation 29. This technique was proposed as an alternative technique to solvent evaporation. 
Lyophilisation has been thought of a molecular mixing technique where the drug and carrier are 
co dissolved in a common solvent, frozen and sublimed to obtain a lyophilized molecular 
dispersion.  
Melt Agglomeration Process 
This technique has been used to prepare SD wherein the binder acts as a carrier. In 
addition, SD(s) are prepared either by heating binder, drug and excipient to a temperature above 
the melting point of the binder (melt- in procedure) or by spraying a dispersion of drug in molten 
binder on the heated excipient (spray-on procedure) by using a high shear mixer30. A rotary 
processor has been shown to be alternative equipment for melt agglomeration. The rotary 
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processor might be preferable to the high melt agglomeration because it is easier to control the 
temperature and because a higher binder content can be incorporated in the agglomerates
31
. The 
effect of binder type, method of manufacturing and particle size are critical parameters in 
preparation of SD(s) by melt agglomeration. Sincethese parameters result in variations in 
dissolution rates, mechanism of agglomerate formationand growth, agglomerate size, 
agglomerate size distribution and densification of agglomerates. It has been investigated that the 
melt in procedure gives a higher dissolution rates than the spray-on procedure with PEG 3000, 
poloxamer 188 and gelucire 50/13 attributed to immersion mechanism of agglomerate formation 
and growth. In addition the melt in procedure also results in homogenous distribution of drug in 
agglomerate. Larger particles results in densification of agglomerates while fine particle cause 
complete adhesion to the mass to bowl shortly after melting attributed to distribution and 
coalescence of the fine particles 32.  
The use of surfactant 
The utility of the surfactant systems in solubilization is well known. Adsorption of 
surfactant on solid surface can modify their hydrophobicity, surface charge, and other key 
properties that govern interfacial processes such as flocculation/dispersion, floatation, wetting, 
solubilization, detergency, and enhanced oil recovery and corrosion inhibition. Surfactants have 
also been reported to cause salvation/plasticization, manifesting in reduction of melting the 
active pharmaceutical ingredients, glass transition temperature and the combined glass transition 
temperature of solid dispersions. Because of these unique properties, surfactants have attracted 
the attention of investigators for preparation of solid dispersions 33, 34.  
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Electro spinning 
Electro spinning is a process in which solid fibers are produced from a polymeric fluid 
stream solution or melt delivered through a millimeter-scale nozzle35. This process involves the 
application of a strong electrostatic field over a conductive capillary attaching to a reservoir 
containing a polymer solution or melt and a conductive collection screen. Upon increasing the 
electrostatic field strength up to but not exceeding a critical value, charge species accumulated 
on the surface of a pendant drop destabilize the hemispherical shape into a conical shape 
(commonly known as Taylor s cone). Beyond the critical value, a charged polymer jet is ejected 
from the apex of the cone (as a way of relieving the charge built-up on the surface of the pendant 
drop). The ejected charged jet is then carried to the collection screen via the electrostatic force. 
The Columbic repulsion force is responsible for the thinning of the charged jet during its 
trajectory to the collection screen. The thinning down of the charged jet is limited by the 
viscosity increase, as the charged jet is dried 
36
. This technique has tremendous potential for the 
preparation of nanofibres and controlling the release of biomedicine, as it is simplest, the 
cheapest 37 this technique can be utilized for the preparation of solid dispersions in future.  
Super Critical Fluid (Scf) Technology: 
This technology has been introduced in the late 1980s and early 1990s, and experimental 
proofs of concept are abundant in the scientific literature for a plethora of model compounds 
from very different areas such as drugs and pharmaceutical compounds, polymers and 
biopolymers, explosives and energy materials, superconductors and catalyst precursor’s dyes and 
biomolecules such as proteins and peptides. From the very beginning of supercritical fluid 
particle generation research, the formation of biocompatible polymer and drug-loaded 
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biopolymer micro-particles for pharmaceutical applications has been studied intensively by a 
number of researcher groups
38 
CFs either as solvent: rapid expansion from supercritical solution 
(RESS) or anti solvent: gas antisolvent (GAS), supercritical antisolvent (SAS), solution 
enhanced dispersion by supercritical fluids (SEDS) and/or dispersing fluid: GAS, SEDS, 
particles from gas-saturated solution (PGSS). Conventional methods, i.e. Spray drying, solvent 
evaporation and hot melt method often result in low yield, high residual solvent content or 
thermal degradation of the active substance39 the supercritical fluid antisolvent techniques, 
carbon dioxide is used as an anti solvent for the solute but as a solvent with respect to the organic 
solvent. Different acronyms were used by various authors to denote micronization processes: 
aerosol solvent extraction system (ASES), precipitation with a compressed fluid antisolvent 
(PCA), gas anti-solvent (GAS), solution enhanced dispersion by supercritical fluids (SEDS) and 
supercritical anti-solvent (SAS). The SAS process involves the spraying of the solution 
composed of the solute and of the organic solvent into a continuous supercritical phase flowing 
concurrently40 use of supercritical carbon dioxide is advantageous as it is much easier to remove 
from the polymeric materials when the process is complete, even though a small amount of 
carbon dioxide remains trapped inside the polymer; it poses no danger to the patient. In addition 
the ability of carbon dioxide to plasticize and swell polymers can also be exploited and the 
process can be carried out near room temperature 
41 
Moreover, supercritical fluids are used to 
lower the temperature of melt dispersion process by reducing the melting temperature of 
dispersed active agent. The reason for this depression is the solubility of the lighter component 
(dense gas) in the forming phase (heavier component) 42 
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Effervescent method: 
Effervescent solid dispersions incorporate sodium bicarbonate and organic acids (citric, 
tartaric or succinic), which react with each other to yield an effervescent mixture. By combining 
poorly soluble drugs with organic acids, one should obtain an effervescent solid dispersion, 
which may increase the dissolution and absorption rates of poorly soluble drugs. Citric 
acid/sodium bicarbonate was found to be the most effective carrier for releasing prednisone and 
primidone and sodium bicarbonate/succinic acid was observed to be the best carrier for 
griseofulvin. Such dispersion can be made by fusion technique as explained above 
43 
Adsorption on insoluble carriers: 
These dispersions are also referred to as surface solid dispersions. In this method, the 
support material is suspended in a solution of the drug followed by evaporation of the solvent. 
The resulting material contains the drug in a “molecularly micronized” state on the surface of the 
carrier. Here, adsorbents maintain the concentration gradient (Cs-Ct), to its maximum, thus 
increasing the dissolution rate. A special technique under these methods is the fluidized bed 
system. It involves first preparation of spraying solution by dissolving both drug and carrier and 
then sugar spheres are charged to fluidized bed granulator and coated. 
These spheres are fluidized by spraying solution and the coated pellets are dried. Solid dispersion 
of poorly water-soluble drug nifedipine was prepared in hydroxypropylmethylcellulose (HPMC) 
on sugar spheres using this technique 44. 
Direct capsule filling: 
Direct filling of hard gelatin capsules with the liquid melt of solid dispersions avoids 
grinding-induced changes in the crystallinity of the drug. This molten dispersion forms a solid 
plug inside the capsule on cooling to room temperature, reducing cross contamination and 
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operator exposure in a dust-free environment, better fill weight and content uniformity was 
obtained than with the powder-fill technique. However, PEG was not a suitable carrier for the 
direct capsule-filling method as the water-soluble carrier dissolved more rapidly than the drug, 
resulting in drug rich 
layers formed over the surface of dissolving plugs, which prevented further dissolution of the 
drug
45,46
. 
 Dropping solution method: 
The dropping method facilitate the crystallization of different chemicals and produces 
round particles from melted solid dispersions. In laboratory-scale preparation, a solid dispersion 
of a melted drug-carrier mixture is pipetted and then dropped onto a plate, where it solidifies into 
round particles. The size and shape of the particles can be influenced by factors such as the 
viscosity of the melt and the size of the pipette. Because viscosity is highly temperature-
dependent, it is very important to adjust the temperature so that when the melt is dropped onto 
the plate it solidifies to a spherical shape47. 
The use of carriers that solidify at room temperature may aid the dropping process. The 
dropping method not only simplifies the manufacturing process, but also gives a higher is 
solution rate. It does not use organic solvents and, therefore, has none of the problems associated 
with solvent evaporation. The method also avoids the pulverization, sifting and compressibility 
difficulties encountered with the other melt methods. Disadvantages of the dropping method are 
that only thermo stable drugs can be used and the physical instability of solid dispersions is a 
further challenge. 
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 Co-precipitation method: 
Co-precipitation is a recognized technique for increasing the dissolution of poorly water 
soluble drugs, so as to consequently improve bioavailability. In this method non solvent is added 
drop wise to the drug and carrier solution, under constant stirring. In the course of the non 
solvent addition, the drug and carrier are co-precipitated to form micro particles. At the end, the 
resulted micro particle suspension is filtered and dried40. The required quantity of polymer and 
the drug were mixed and then solvent was added to obtain clear solution. The Solution was first 
dried under vacuum at room temperature and kept inside incubator (370c) for 12 hrs. Finally it 
was passed through sieves4148. 
Nanoparticles 
Nanoparticles are particles between 1 and 100 nanometers in size. In nanotechnology, a 
particle is defined as a small object that behaves as a whole unit with respect to its transport and 
properties. Particles are further classified according to diameter. Ultrafine particles are the same 
as nanoparticles and between 1 and 100 nanometers in size. Coarse particles cover a range 
between 2,500 and 10,000 nanometers. Fine particles are sized between 100 and 2,500 
nanometers. Nanoparticles are of great scientific interest as they are, in effect, a bridge between 
bulk materials and atomic or molecular structures. A bulk material should have constant physical 
properties regardless of its size, but at the nano-scale size-dependent properties are often 
observed. Thus, the properties of materials change as their size approaches the nanoscale and as 
the percentage of atoms at the surface of a material becomes significant. For bulk materials 
larger than one micrometer (or micron), the percentage of atoms at the surface is insignificant in 
relation to the number of atoms in the bulk of the material. The interesting and sometimes 
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unexpected properties of nanoparticles are therefore largely due to the large surface area of the 
material, which dominates the contributions made by the small bulk of the material. 
Nanoparticles often possess unexpected optical properties as they are small enough to confine 
their electrons and produce quantum effects. For example gold nanoparticles appear deep-red to 
black in solution. Nanoparticles of yellow gold and grey silicon are red in color. Gold 
nanoparticles melt at much lower temperatures (~300 °C for 2.5 nm size) than the gold slabs 
(1064 °C); Absorption of solar radiation is much higher in materials composed of nanoparticles 
than it is in thin films of continuous sheets of material. In both solar PV and solar thermal 
applications, controlling the size, shape, and material of the particles, it is possible to control 
solar absorption.  
Other size-dependent property changes include quantum 
confinement in semiconductor particles, surface Plasmon resonance in some metal particles 
and superparamagnetism in magnetic materials. What would appear ironic is that the changes in 
physical properties are not always desirable. Ferromagnetic materials smaller than 10 nm can 
switch their magnetization direction using room temperature thermal energy, thus making them 
unsuitable for memory storage. Suspensions of nanoparticles are possible since the interaction of 
the particle surface with the solvent is strong enough to overcome density differences, which 
otherwise usually result in a material either sinking or floating in a liquid. The high surface area 
to volume ratio of nanoparticles provides a tremendous driving force for diffusion, especially at 
elevated temperatures. Sintering can take place at lower temperatures, over shorter time scales 
than for larger particles. In theory, this does not affect the density of the final product, though 
flow difficulties and the tendency of nanoparticles to agglomerate complicates matters. 
Moreover, nanoparticles have been found to impart some extra properties to various day to day 
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products. For example, the presence of titanium dioxide nanoparticles imparts what we call the 
self-cleaning effect, and, the size being nano-range, the particles cannot be observed. Zinc 
oxide particles have been found to have superior UV blocking properties compared to its bulk 
substitute. This is one of the reasons why it is often used in the preparation of sunscreen 
lotions, and is completely photostable.  Clay nanoparticles when incorporated into polymer 
matrices increase reinforcement, leading to stronger plastics, verifiable by a higher glass 
transition temperature and other mechanical property tests. These nanoparticles are hard, and 
impart their properties to the polymer (plastic). Nanoparticles have also been attached to textile 
fibers in order to create smart and functional clothing.Metal, dielectric, 
and semiconductor nanoparticles have been formed, as well as hybrid structures (e.g., core–shell 
nanoparticles). Nanoparticles made of semiconducting material may also be labeled quantum 
dots if they are small enough (typically sub 10 nm) that quantization of electronic energy 
levels occurs. Such nanoscale particles are used in biomedical applications as drug 
carriers or imaging agents. Semi-solid and soft nanoparticles have been manufactured. A 
prototype nanoparticle of semi-solid nature is the liposome. Various types of liposome 
nanoparticles are currently used clinically as delivery systems for anticancer drugs and vaccines. 
Nanoparticles with one half hydrophilic and the other half hydrophobic are termedJanus and are 
particularly effective for stabilizing emulsions. They can self-assemble at water/oil interfaces and 
act as solid surfactants.50 
Nanoparticle Applications in Medicine 
The surface change of protein filled nanoparticles has been shown to affect the ability of 
the nanoparticle to stimulate immune responses. Researchers are thinking that these 
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nanoparticles may be used in inhalable vaccines. Researchers at Rice University have 
demonstrated that cerium oxide nanoparticles act as an antioxidant to remove oxygen free 
radicals that are present in a patient's bloodstream following a traumatic injury. The 
nanoparticles absorb the oxygen free radicals and then release the oxygen in a less dangerous 
state, freeing up the nanoparticle to absorb more free radicals. Researchers are developing ways 
to use carbon nanoparticles called nanodiamonds in medical applications. For 
example nanodiamonds with protein molecules attached can be used to increase bone growth 
around dental or joint implants. Researchers are testing the use of chemotherapy drugs attached 
to nanodiamonds to treat brain tumors. Other researchers are testing the use of chemotherapy 
drugs attached to nanodiamonds to treat leukemia.51 
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LITERATURE REVIEW 
D.m.patel, r.r.shah, et al.,have studied solid dispersions of piroxicam with peg-4000, pvp   k-
30, prepared by solvent evaporation technique and release profile was studied in USP xxiii 
dissolution apparatus in simulated gastric fluid. It was found that piroxicam release was much 
higher from solid dispersions than pure drug sample.52 
 
M.Gopalrao, R.Suneetha, et al.,Observed that improved dissolution of naproxen solid 
dispersion with pvp, peg-4000, peg-6000.peg-20000, methyl cellulose and β-cyclodexrin than the 
pure drug powder.  Among the carrier studied it was found that naproxen b-cyclodextrin solid 
dispersion showed highest improvement in dissolution.53  
M.M.Soniwala, P.R..Patel, et al.,studied the dissolution proile of rofecoxiib by formulating 
solid dispersions of rofecoxin with various hydrophilic carriers i.e. peg-6000, pvp k-30, Eudragit 
e-100 and inclusion complex of β-cyclodextrin in 0.1n hc1. Rofecoxib forms eutectic mixture 
with peg-6000. Inclusion complex with β-cyclodextrin showed enhanced dissolution rate 
compared to other formulation and pure drug.
54 
K.P.R.Choudhary, Sheikh Srinivasa, et al., showed that complex of itraconazole with β-
cyclodextrin and hydroxyl propy1 β-cyclodextrin in aqueous solution has improved solubility 
and dissolution of itraconazole. The complexes were prepared by kneading method and co-
vaporization. Higher dissolution rate was observed in kneaded complexes than co-vaporization 
method.55 
Nagarsenker M.S.et al.reported the influence of Hydroxy propy1 β-cyclodextrin on dissolution 
of piroxicam and on irritation to stomach or rat upon oral administration. The dissolution of 
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piroxicam from solid dispersions was found to have improved considerably over that of the pure 
drug alone. Co-evaporated and freeze dried dispersions caused significant reduction in irritation 
to stomach mucosa of rat upon oral administration.
56 
K.P.R.Choudhary, R. Hymnet al.Studied solid dispersions of Meloxicam with PVP, HPMC, 
HPC and PEG-6000 & solvent deposited system on lactose, soluble starch, microcrystalline 
cellulose, discalcuim phosphate. A marked enhancement in the dissolution rate and dissolution 
efficiency of Meloxicam was observed with all solid dispersions. Among all PVP solid 
dispersion showed highest dissolution rate enhancement.57 
 
Manimaran.V, Damoadharanet al.,prepare solid dispersion of Glibenclamide using different 
carriers such as PEG 6000, polyvinylpyrolidine (PVP) andPoloxamers in different ratios (1:1, 
1:2, 1:3, 1:4 and 1:5) by Solvent Evaporation method. Drug carrier interactions were analysed by 
X‐rayDiffraction and Infra‐Red Spectroscopy. Dissolution studies using the USP paddle method 
were performed for all solid dispersions. All solidDispersions showed increased dissolution rate 
as compared to pure Glibenclamide and PVP was found to be better than PEG and Poloxamer. 
TheTablets were formulated using solid dispersion of Glibenclamide containing PVP as carrier. 
The tablets containing solid dispersion exhibited betterDissolution profile than commercial 
tablets. Thus solid dispersion technique can be successfully used for improvement of dissolution 
ofGlibenclamide.58 
.P.R. Choudhary, G. Kamalkara, et al.,prepared complex of nifedipine with β-cyclodextrin 
and Hydroxy propy1 β-cyclodextrin and the possibility of improving solubility and the 
dissolution rate of Nifedipine-Cyclodextrin inclusion complexes in the design of mucoadhesive 
tablets for sustained release were investigated; the phase solubility studies also were carried out. 
The solubility and dissolution rates were markedly enhanced by complex formation. 
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Mucoadhesive tablets formulated with Nifedipine gave very low release, whereas the tablet 
prepared with cyclodextrin complex showed controlled and complete release.
59 
V. Kusum Devi, P. Vijayalaxmiet al.,prepared solid dispersions of celecoxib with different 
carriers in different ratio and subjected to solubility and dissolution rate studies. All formulation 
showed improve solubility as well as dissolution rate am one which PVP-Viny1 Acetate polymer 
showed highest dissolution rate that other carriers.
60 
NeelamSeedheret al.examined the solubility enhancement of Cox-2 inhibitors, celecoxib, 
rofecoxib, meloxicam, and nimesulide, using a series of pure solvents and solvent mixtures. 
Water, Alcohols, Glycols, Glycerol, and Polyethylene Glycol 400 (PEG 400) were used as 
solvents and water-Ethanol, Glycerol-Ethanol, and polyethylene Glycol-Ethanol were used as 
mixed-solvent systems. The aqueous solubility of clecoxib, Rofecoxib, and Nimesulide was 
enhanced significantly by using Ethanol as the second solvent.61 
Taneja L. N. et al.,have reported the in-vitro characterization and bioavailability assessment of 
solid dispersions of ketoprofen.  The polymers used are PEG-6000 and poloxamer 188. Both 
solid dispersions and physical mixtures showed improved dissolution62 
R.Kaliselvam, G. S. Prasad et al.,prepared Mebendazole and β-cyclodextrin molecular 
inclusion complexes, Mebendazole solid dispersion with PEG 6000 by solvent method in 
different ration and physical mixtures. The enhancement of dissolution of Mebendazole depends 
on carrier used and nature of formula i.e. physical mixture, solid dispersion or molecular 
inclusion complex. Dissolution rate and dissolution efficiency were improved by both molecular 
inclusion complex and solid dispersion in all ratio that physical mixture and pure drug.
63 
Kuchekar B.S.et al.have reported on solid dispersions of paracetamol using β-cyclodextrin and 
dextrin. Uniform drug distribution was found in all solid dispersions. Swati Rawat, Laila F Et.el., 
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studied five marketed formulation of Rofecoxib to estimate their dissolution rate and compared 
with two laboratory made test formulations prepared with β-cyclodextrin by kneading method.  
Study showed poor drug release characteristic from marketed formulation as compared to 
laboratory made formmulation.
64 
S. Jagatpal Reddy, U. R. Gadsoorkaret al.,prepared solid dispersion of Glicalzide with PEG 
4000, PEG 6000 by solvent method and subjected to dissolution studies. Pure Gliclazide showed 
only 45% dissolution after 60 min up PH 7.4 buffer where as solid dispersions prepared showed 
increased dissolution that pure drug.65 
Suresh D. Kumavat*1, YogeshChaudhariet al.,enhance the solubility of poorly water soluble 
drug Glibenclamide via the Solid Dispersion technique by Spray drying method. Solid 
dispersions (SD) of  libenclamide-Plasdone S630in the ratio of  1:1, 1:2, 1:4, 1:6 and 1:8 were 
prepared in an attempt to increase the solubility and dissolution rate of the drug. Solubility, 
dissolution, Scanning electron microscopy (SEM), differential scanning calorimetry (DSC) and 
Fourier transform infrared spectroscopy (FTIR) of solid dispersions, physical mixtures (PM) and 
Glibenclamidewere evaluated. Both solubility and dissolution of drug solid dispersions were 
significantly greater than those observed for physical mixtures and intact pure Glibenclamide. 
The differential scanning calorimetry indicated that the high energy amorphous Glibenclamide 
was obtained from all solid dispersions. It was found that the optimum weight ratio for 
Glibenclamide-Plasdone S630 is 1:8. The 1:8 solid dispersion shows highest Dissolution rate 
owing to itsamorphous nature and reduced particle size.
66 
MuktaKhadilkar, Jasmine Avari, et al.,studied solid dispersion of ketoprofen prepared by 
fusion method using Mannitol and PEG-6000 as carriers.  All solid dispersions showed increased 
dissolution rate when compared with pure Ketoprofen release.67 
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Parikh R.K. Mansuri N.S. et al.,presented dissolution enhancement of Nimesulide using 
complexation and salt formulation technique.  The complex of Nimesulide with β 
cyclodextrinand salt with L-Arginine and L-Lysine shows significant increase in the dissolution 
of the drug as compared to pure drug.
68 
Ganesan V., Sandhya K. G. et al.,studied physical solubility and dissolution rate of 
Flurbiprofen suspension employing its solid dispersions with HMS, PVP, PEG and Dextrin and 
were evaluated for particle size, physical stability and dissolution rate, Flurbiprofen solid 
dispersion exhibited good suspendability and gave higher dissolution rate than those formulated 
with Flubiprofen alone.69 
SanjulaBaboota, Suraj P. Agrawalet al.,formulated Meloxicam Cyclodextrin inclusion 
complexes and incorporated to tablets containing inclusion complexes. β-cyclodextrin, Hydroxy 
propy1 β-Cyclodextrin inclusion complexes were  prepared by freeze drying method and 
evaluated by FTIR, X-RD, DTA , SEM,. The solubility and in-vitro release indicated increased 
solubility and dissolution rate compared to free drug.7 
SengodanGurusamy, Vijaykumaret al.,prepared solid dispersion of Meloxicam with skimmed 
milk and evaluated for solubility and dissolution profile. Result showed that the solubility of the 
solid dispersion of the drug was three times greater than pure drug, also significant improvement 
in rate of dissolution to drug than physical mixture.
71 
KashappaGoud H. Desai et al.,carried our solubility studies of valdecoxib in presence of 
carriers, co-solvent and surfactant.  Carriers used were Mannitol, peg4000, peg6000, peg8000 
and urea.  Surfactant tween20, tween 80 and SLS and co-solvent like ethanol, methanol and 
glycerol.  The solubility of valdecoxib was found increased more by PEG4000 as carrier.  
Ethanol as a solvent and SLS as a surfactant compared to others and pure drug.72 
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ChengshengLill. L. et al.,presented a study to enhance dissolution rate of rofecoxib using solid 
dispersion with urea.  A systematic increase in the solubility behaviors of Rofecoxib was 
observed with increase in concentration of carriers in water.
73 
Pan R. N., Chon J. H. et al.,studied solid dispersion system of water insoluble piroxicam in 
PEG-4000 and urea, prepared by fusion and solvent method. The in-vitro dissolution studies 
showed that the dispersion system containing piroxicam with carriers gave faster dissolution than 
simple physical mixtures and pure drug sample.7 
F.Cilurzo, P. Mingheti., et al.,studied sublingual administration of nifidipine solid dispersions 
by using sublingual i.e. low viscosity HPCM in different ratios were prepared by spray drying 
technique and the structure was studied. Dissolution properties from solid dispersions were 
verified; it showed improved dissolution than physical mixture of nifidipine with HPMC and 
pure sample of nifidipine.75 
Duncam Q.M. Craig et al.,studied mechanism of drug release from solid dispersion in wear 
soluble in polymer, and observed the enhanced dissolution rate and efficiency due to formation 
of eutectic mixture and reduced particle sizes of various drugs due to formation of solid 
dispersions.
76 
S.  Verneyen, N. Balton., et al.,presented the mechanism of increased dissolution of Diazepam 
&Temazepam from PEG-6000 solid dispersions.  This study clearly showed that addition with 
PEG-6000 of Diazepam and Temazepam improves their dissolution rate.  Solid dispersions 
prepared by solvent evaporation method and fusion method showed enhanced dissolution than 
physical mixtures and pure drug sample.
77 
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SudhaR.Vippogunta, et al.,studied solid state characterization of Nifedipine solid dispersions 
prepared with pluronic F-68 and Gelucire 50/13.  They enhanced rate and extent of water uptake 
by formulation.  The dissolution rate was determined and was found to be enhanced.
78 
Ahmad M. Abdul Fatteha,et al.Performed study on low aqueous solubility and bioavailability 
of Halofantrine and suggested formulation of solid dispersions with PVP K-30, PEG-8000, 
Gelucir 44-14, Sodium Taurocholate and also physical mixtures. The dissolution of Halofantrine 
from the physical mixtures was higher than pure form.  The formulation of Halofantrine in solid 
dispersions significantly improved dissolution rate comparative to physical mixtures and pure 
form.79 
F.Damian, N. Blaton, et al.,studied physical stability of solid dispersion of an antiviral agent 
UC-781 with PEG-6000, Gelucir 44/14 and PVP K30 prepared by solvent evaporation method 
and fusion method.  Solid dispersions were stored from 0 to 25 0C (25% RH) and their 
physicochemical properties were analyzed, also studied rate of dissolution from solid dispersion 
with storage time.  All solid dispersion showed sufficient stability and enhanced dissolution 
rate.80 
Omar Saeedet al.,(2009) reported about Knowledge of modifiable risk factors of Coronary 
Atherosclerotic Heart Disease (CASHD) among a sample in India. Study suggests that there is a 
lack of awareness among a sampled Indian population regarding modifiable risk factors of 
CASHD.
81 
Laurent P et al., (2012) proposed a hot melt dispersion method to prepare new sustained 
release ibuprofen composite microparticles of a solid lipid at ambient temperature using cetyl 
alcohol. The dispersion of colloidal silicon dioxide nanoparticles (hydrophilic Aerosil® 200 or 
hydrophobic Aerosil® R974) either in the oily phase or in the aqueous phase led to the 
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preparation of large (about 400µm diameter) surfactant free; free-flowing particles. Crystalline 
state of ibuprofen and lipid has an influence on the drug release kinetics thus increase in the 
size of the composite solid lipid microparticles.
82
  
Rosanna Tursilli et al., (2007) projected in their work that a Solid lipid microparticles (SLM) 
loaded with the sun screen agent, octyl-dimethylaminobenzoate (ODAB), enhances sunscreen 
photostability. The microparticles were produced by melt dispersion technique using 
glycerylbehenate as lipidic material and poloxamer 188 as an emulsifier. The prepared SLMs 
achieved a reduction of sunscreen photodegradation in the hydrogel vehicle (ODAB loss is 
decreased). Therefore, the efficacy of the ODAB-loaded SLMs was markedly affected by the 
vehicle.83 
SeverineJaspart et al., (2007) proposed Solid lipid microparticles (SLM) as a drug carrier 
compared to liposomes and polymeric microspheres. The aim of this work is to use SLMs to 
impart a sustained release profile to a model drug, salbutamol acetonide (SA). SA-loaded 
SLMs were prepared by hot emulsion technique followed by high-shear homogenization. In 
vitro release study of SA from SLMs showed that the release rate of a drug has increased with 
SA loading but remained in every case lower than the dissolution rate of pure SA.
84 
Helmut Reithmeier et al., (2001) prepared SLMs using somatostatin, a peptide with a high 
therapeutic potential. It has a short biological half-life hence encapsulated with in 
microparticles by a modified solvent evaporation and melt dispersion method. The 
encapsulation efficiency of the peptide into glyceryltripalmitatemicroparticles was found to be 
influenced by method of its preparation and the physical state of peptide to be incorporated. 
Microparticles prepared by melt dispersion method showed better results than the solvent 
evaporation technique.85  
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Giovannelli L et al., (2005) recommended SLMs using Hot Air Coating (HAC) technique to 
prepare microparticulate systems containing nifedipine. Binary mixtures constituting of 
nifedipine and cetearylalcohol (CA) in different proportions (30:70,50:50, 70:30) were studied 
and homogenized by milling or mixing. Experimental results showed evidence that milling 
pre-treatment of mixtures, has significant effects on the properties of the lipid coated 
microparticles.
86 
Sudhir S C et al., (2010) showed Paclitaxel delivered intratumorally in PLGA microparticles, 
or the commercial Paclitaxel Injection. In this the larger PLGA microparticles adheres to 
mucus on the cell surface and release paclitaxel locally, and enhances cellular association of 
paclitaxel. At last it was concluded that, sustained release of PLGA microparticles increased 
cellular concentration, and enhanced anti tumor efficacy of paclitaxel compared to 
nanoparticles and Paclitaxel Injection.87 
NicoletaButoescu et al., (2009) suggested that Superparamagnetic iron oxide nanoparticles 
(SPIONs) are attractive materials that have been widely used in medicine for diagnostic 
imaging and therapeutic applications. SPIONs and corticosteriod dexamethasone acetate 
(DXM) are co-encapsulated into PLGA microparticles for treating local inflammatory 
conditions such as arthritis. Results showed that the microparticles have an excellent 
biocompatibility with synoviocytes and they are internalized through a phagocytic process. 
Microparticles used as a carrier represent a suitable magnetically retainable intra-articular drug 
delivery system for treating joint diseases such as arthritis or osteoarthritis.
88 
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PLANE OF WORK 
 The study was planned to carry out as follows, 
Stage I 
A) Preliminary  investigations  
i. Screening ofCarriers. 
ii. Effect of carries on Solubility 
Stage II 
B) Formulation of solid dispersions for different carriers. 
i. Physical mixture. 
ii. Solvent evaporation method. 
iii. Droppings method. 
iv. Wet grinding method. 
   
C) Formulation of nanoparticles by different methods. 
i. Sonication method. 
ii. Antisolvent method. 
 To perform in vitrodissolution studies and dissolution rate of prepared formulations and 
marketed available drug using dissolution apparatus (LABINDIA, DS 2000, Mumbai, India). 
Stage III 
D) Characterization of ideal formulations 
i. Drug Content in formulations 
ii. X-ray Diffraction studies 
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iii. Infrared Spectroscopy 
iv. Chromatographic study 
v. Particle Size Analysis 
StageIV 
E) kinetic analysis of dissolution data 
                           The release rate and mechanism of drug release from the prepared formulations 
were analyzed by fitting the dissolution data into various release models such as: 
i. zero order 
ii. First order 
STAGE V 
F) Stability Studies of some ideal batches. 
STAGE VI 
G)   Comparison of marketed available formulation. 
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DRUGPROFILE. 
Glibenclamide and diabetes
89 
In recent years, developed nations have witnessed an explosive increase in the occurrence 
of diabetes mellitus (DM) predominantly related to lifestyle changes and the resulting surge in 
obesity. The metabolic consequences of prolonged hyperglycemia and dyslipidemia (including 
accelerated atherosclerosis, chronic kidney disease, and blindness) impose an enormous burden 
on patients with diabetes mellitus and on the public health system. Improvements in our 
understanding of the pathogenesis of diabetes and its complications and in the therapy and 
prevention of diabetes are critical to meeting this health care challenge. The Glibenclamide 
nanoparticles may be favor treatment of type 2 diabetes mellitus as a chronic disease and perhaps 
will provide the following 
ADVANTAGES:  
a) Decreased drug doses and side effects  
b) Enhanced patient compliance. 
Furthermore, some studies have shown that absorption may be decrease in hyperglycemic 
patients and nanoparticles may increase absorption of drug by optimizing its interaction with the 
site of action and also by directly transporting it through the intestinal mucosa to the systemic 
circulation. 
Appearance and solubility: 
Glibenclamide is a white or almost white, crystalline powder. It is practically insoluble in 
water and in ether, slightly soluble in alcohol and in methyl alcohol, ethanol, and acetone and 
sparingly soluble in dichloromethane. It dissolves in dilute solutions of alkali hydroxides. 
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Structure formula 
. 
 
Fig:4.1 .Molecular structure of Glibenclamide. 
 Mechanism of action: 
Glibenclamide, like other Sulfonylurea’s, causes hypoglycemia by stimulating insulin 
release from pancreatic ß cells. Its effect in the treatment of diabetes, however, is more complex. 
The acute administration of sulfonylurea’s to type 2 DM patients’ increases insulin release from 
the pancreas. Sulfonylureas also may further increase insulin levels by reducing hepatic 
clearance of the hormone. In the initial months of sulfonylurea treatment, the fasting plasma 
insulin levels and insulin responses to oral glucose challenges are shown to be increased. With 
chronic administration, circulating insulin levels decline to those that existed before treatment, 
but despite this reduction in insulin levels, reduced plasma glucose levels are maintained. 
Pharmacokinetics: 
Glibenclamide is readily absorbed from the gastrointestinal tract and the pike plasma 
concentrations can usually occur within 2 to 4 hours. It is extensively bound to plasma proteins 
and absorption may be slower in hyperglycemic patients and may differ upon the particle size of 
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preparation used. It is almost completely metabolized and the principle metabolite is very weekly 
active in the liver. Approximately 50% of a dose is excreted in the urine and 50% via the bile in 
to the feaces. 
Uses and administration: 
Glibenclamide is a sulphonylurea hypoglycemic. It is orally administrated in the 
treatment of type 2 diabetes mellitus and has duration of action of up to 24 hours. The usual 
initial dose of conventional formulations in type 2 diabetes mellitus is 2.5 to 5 mg daily with 
breakfast. In the case of micronized preparations of Glibenclamide, the drug is formulated with a 
smaller particle size, and display enhanced bioavailability. The usual initial dose of such 
preparation (GlynaseTM) is 1.5 to 3 mg daily. 
Adverse effects 
Gastrointestinal disturbances such as nausea, vomiting, heartburn, anorexia, diarrhea, and 
a metallic taste may occur with sulfonylurea and are usually mild and dose dependent; increased 
appetite and weight gain may also occur. Skin rashes and pruritus and photosensitivity have been 
reported. Rashes are usually hypersensitivity reactions and may progress to more serious 
disorders. Furthermore mild hypoglycemia may be seen. Severe hypoglycemia is usually an 
Indication of over dosage and is relatively uncommon. Hypoglycemia is more likely with long-
acting sulphonylurea such as chlorpropamide and Glibenclamide, which have been associated 
with severe, prolonged, and sometimes fatal hypoglycemia. 
Dosage forms 
The following dosage forms are currently used for Glibenclamide: 
BP 1998: Glibenclamide tablets; 
USP 23: glyburide tablets. 
Other names: micronase, diabeta 
AKCP DEPARTMENT OF PHARMACEUTICS  Page | 43 
 
 
POLYMER PROFILE 
Polymer profile 
90 
UREA 
Nonproprietary Name: 
 Urea 
Synonyms 
 Berural70, Carbamide, Nimin. 
Chemical Name 
 Urea 
Molecular Formula: 
 CH4 NO2 
Molecular Weight: 
 60.06 
Melting Point 
 133
0 
C 
Functional Category 
 Binder, Sealant, Filler, Analytical reagent and Humectant. 
Description: 
 White prismatic odorless crystals/ powder and saline in taste 
Solubility: 
 Freely soluble in water, 1gm/100ml of ethanol, 10.7gm/100ml of methanol, 150gm/ml of 
glycerol. 
Stability and Storage: 
 Stable in solid state and should be stored in tightly closed container, in cool and dry 
place. 
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POLYETHYLENE GLYCOL-6000 
Nonproprietary Name: 
 BP: Macrogol 300 
 USPNF: Polyethylene glycol 
Synonyms 
 Breox PEG; Carbowax; Polyoxyethylene glycol; 
Chemical Name 
 α- Hydro-ω-Hydroxy-poly (oxy-1,2-ethanediyl)[25322-68-3] 
Structure formula 
 
 
Fig:4.2 .Molecular structure of PEG. 
 
Molecular Formula: 
 HOCH2 (CH2OCH2) mCH2OH 
Molecular Weight: 
 5000-7000 
Melting Point 
 55-630 C 
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Functional Category 
 Polymer, suppository base, ointment base, emulsion stabilizer. 
Description: 
 White prismatic odorless crystals/ powder and bitter in taste 
Solubility: 
 Soluble in water, acetone, alcohol, dichloromethane,ethanol and methanol 
Stability and Storage: 
 Stable in solid state and should be stored in tightly closed container, in cool and dry 
place. 
Chitosan
91 
 Nonproprietary Names 
BP: Chitosan HydrochloridePhEur: Chitosan Hydrochloride 
 Synonyms 
2-Amino-2-deoxy-(1,4)-b-D-glucopyranan; chitosani hydrochloridum;deacetylated chitin; 
deacetylchitin; b-1,4-poly-D-glucosamine;poly-D-glucosamine; poly-(1,4-b-D-
glucopyranosamine). 
 Chemical Name: 
Poly-b-(1,4)-2-Amino-2-deoxy-D-glucose [9012-76-4] 
 Molecular Weight 
Molecular weight by 10 000–1 000,  
 Functional Category 
Coating agent; disintegrant; film-forming agent; mucoadhesive; tablet binder; viscosity 
increasing agent. 
 Description 
Flakes Fiber formation is quite common during precipitation and 
TheChitosan may look ‘cotton like’. 
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Solubility  
Sparingly soluble in water;  practically insoluble in ethanol (95%), other organic solvents, and 
neutral or alkali solutions at pH above approximately 6.5. Chitosan dissolves readily in dilute 
and concentrated solutions of most organic Stability and Storage Conditions Chitosan powder is 
a stable material at room temperature, although it is hygroscopic after drying. Chitosan should be 
stored in a tightly closed container in a cool, dry place. The PhEur 6.5 specifies that Chitosan 
should be stored at a temperature of 2–88C. 
 
 Incompatibilities 
Chitosan is incompatible with strong oxidizing agents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AKCP DEPARTMENT OF PHARMACEUTICS  Page | 47 
 
 
LIST OF EQUIPMENTS/INSRTRUMENTS 
Table No5.1 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No Equipments/Instruments Manufacturer/Source 
1. Electronic Balance SHIMADZU ELB 300 
2. Hot plate SRI MAHALAKSHMI 
INSTRUMENTS 
MADURAI 
3. Hot Air Oven ELCON 
4. Magnetic Stirrer REMI 
5. TLC Plate Astra Scientific Systems(p) Ltd. 
VM-02 
6. Dissolution Test Apparatus LABINDIA  DISSOO 2000 
7. FT IR SHIMADZU 
8. UV spectrophotometer SHIMADZU  UV-1700 
9. XRD BRUKER  ECO D8 
10. pH Meter AGRONIL 511 
11. Microscope A.K.C.P 
12 Size analyzer  Malvern 
13 Tablet Compression machine Rimek mini press-1 
14 Disintegration test apparatus Rolex 
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MATERIALS AND MANUFACTURER 
Table No 6.1: 
 
 
   
  
 
 
S.No NAME OF THE 
MATERIAL 
SOURCE/SUPPLIER/MANUFACTURER 
1. GLIBENCLAMIDE GIFT SAMPLE FROM PHARMAFABRIKAN 
2. PEG 6000 GIFT SAMPLE FROM CAPLINPOINT 
3. UREA NICE LABORATORIES KOCHI, KERALA. 
4. CHITOSAN SISCO RESEARCH LABORATORIES 
5. METHANOL HIMEDIA MUMBAI 
6. 
 
ETHANOL CHANGSHU YANGYUAN CHEMICAL CHINA 
7. ACETONE HI-PURE FINE CHEM INDUSTRIES, CHENNAI. 
8. CHLOROFORM HIMEDIA MUMBAI 
9. SPANE 80 OXFORD  LABORATORY  MUMBAI 
10. Hcl RANKEM  LABORATORY  AMBATTUR 
11. Kcl FISCHER CHEMIC LTDCHENNAI 
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EXPERIMENTAL WORKS 
DEVELOPMENT OF CALIBRATION CURVE:
 
Preparation of Buffer Solution (pH-1.2)
92 
        250ml of 0.2Ml Potassium chloride solution (14.911 gm of KCL in 1000ml) and 425ml 
of0.2N Hydrochloric acid (7.292 gm in 1000ml) were mixed properly and the volume was made 
up to 1000ml with distilled water. 
Preparation of Standard Solution of Glibenclamide
93 
  A Solution of 5mg Glibenclamide was prepared by dissolving in 100ml methanol, from 
which 1ml was withdrawn in separate volumetric flask and diluted to 10ml with Hcl buffer to 
produce 5µg/ml concentration and absorbance at 302 nm 1 
Preparation of Working Solution: 
       From standard solution, 0.5, 1, 1.5, 2, 2.5, and 3ml was withdrawn in six 10ml volumetric 
flasks and diluted to 10ml with HCL buffer pH 1.2 to produce concentration 2.5, 5, 7.5, 10, 12.5 
and 15 respectively. The solutions were analyzed by U.V. spectrophotometer at 302nm and 
results were recorded. The calibration graph was plotted as concentration on X-axis Vs 
absorbance onY-axis  
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Table No 7.1: 
Standard curve of Glibenclamide 
 
 
 
 
 
 
 
 
Figure 7.1 
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Standard curve of Glibenclamide
S.No Concentration (µg/ml) Slope Avg slope 
1 2.5 0.0164  
 
0.0160 
 
2. 5.0 0.0160 
3. 7.5 0.0153 
4. 10.0 0.0163 
5. 12.5 0.0158 
6. 15.0 0.0164 
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PRILIMINARY INVESTIGATIONS: 
a) SCREENING OF CARRIER94 
Carriers used for study were PEG-6000, UREA, βCyclodextrin,PVP K30 and CITOSAN. 
The Solid dispersion of PEG6000, Urea, PVP K90 and Chitosan were prepared by 
physical mixing   method, Solid dispersion of PEG 6000, Urea and PVP K30 were 
prepared by solvent evaporation and Dropping method. Chatoyant and PVPK30 were 
prepared by wet grinding method using ratio 1:1 of Drug: Carrier and were screened for 
yield, texture and color, physical characteristics and suitability in preparation.   
b) Effect of Carriers  solubility: 
Known amount of samples of solid dispersion and nanoparticles was added in 50 ml of 
distilled water and kept for 24 hrs occasional stirring. After 24hrs contents were filtered 
by the wattman filter paper, and appropriate dilutions were made with 0.2M Hcl buffer 
and absorbance of the resultant solution was measured at 302 nm and extrapolated on 
standard graph to determine the concentration. 
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FORMULATION OF SOLID DISPERSIONS 
Preparation of solid dispersion by Physical mixture method
95 
Physical Mixture of drug with PEG6000, Ureaand Chitosan were prepared by separately 
at three different ratios 1:1, 1:2 and 1:3. Accurately   weighed 100mg drug was taken and mixed 
with 100,200 and 300mg of PEG6000, Ureaand Chitosan Physical mixture were prepared by 
triturating the powder mix in pestle mortar   for 3 to 5 minutes. Subsequent to this the mixture 
was passed through sieve number 60 having meshsize of 250µm.Thenaccuratelyweighed 50 mg 
of physical mixture of Glibenclamide was used sprinkled directly to surface of the dissolution 
medium. And dissolution studies were carried out with   TYPEII (LABINDIA, DISSO 2000) 
dissolution apparatus at a stirring speed of 100 rpm and 0.2 M hydrochloric acid at (pH 1.2) 37 ± 
0.5°C as the dissolution medium. 
Preparation of solid dispersion by Solvent evaporation   method
96 
In Solvent evaporation   method, drug with PEG6000 and Urea were prepared by 
separately at three different ratios 1:1,1:2 and 1:3. Accurately   weighed 100mg drug was taken 
and mixed with 100,200 and 300mg of PEG6000 and Urea   Were dissolved in methanol 
andconstant stirring. Solution was evaporated   under low pressure to get the solid dispersion. 
Then accuratelyweighed 50 mg solventevaporated of Glibenclamide was used sprinkled directly 
to surface of the dissolution medium. And dissolution studies were carried out withTYPE II 
(LABINDIA, DISSO 2000) dissolution apparatus at a stirring speed of 100 rpm and 0.2 M 
hydrochloric acid at (pH 1.2) 37 ± 0.5°C as the dissolution medium. 
Preparation of solid dispersion by dropping   method
97 
In Dropping   method, drug with PEG6000 and Urea Were prepared by separately at three 
different ratios 1:1,1:2 and 1:3. Accurately   weighed 100mg drug was taken and mixed with 
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100,200 and 300mg of PEG6000 and Urea. A solid dispersion of a melted drug and carrier is 
pipette and then dropping onto a plate, where it solidified in to round or spherical particles. Then 
accuratelyweighed 50 mg of Dropping Glibenclamide was used sprinkled directly to surface of 
the dissolution medium.  And dissolution studies were carried out withTYPE II (LABINDIA, 
DISSO 2000) dissolution apparatus at a stirring speed of 100 rpm and 0.2 M hydrochloric acid at 
(pH 1.2) 37 ± 0.5°C as the dissolution medium. 
Preparation of solid dispersion by Wet grinding method
98 
In wet grinding  method drug  with Chitosan  were prepared by separately at three 
different ratios  1:1,1:2 and 1:3 Accurately   weighed 100mg drug was taken and mixed with 
100,200 and 300mg of Chitosan in mortar porcelain for 5 minutes .Methanol was then  added to 
the  mixture just enough to form dough texture. The mixture was grinded for 30 minutes. The 
obtained   dough was dried at 500C for 8 hrs, and thenaccuratelyweighed 50 mg of 
Glibenclamide was used sprinkled directly to surface of the dissolution medium.  And 
dissolution studies were carried out withTYPE II (LABINDIA, DISSO 2000) dissolution 
apparatus at a stirring speed of 100 rpm and 0.2 M hydrochloric acid at (pH 1.2) 37 ± 0.5°C as 
the dissolution medium. 
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FORMULATION OF NANOPARTICLES 
Sonication method
99 
The nanoparticles were prepared by an emulsion–solvent evaporation method. Typically, 
a solution of 100 mg of Glibenclamide in ethanol was mixed with 10mL of aqueous solution. 
This mixture was homogenized for 10 min by vortex and then sonicated using a micro tip probe 
sonicator set at 55Wof energy output (SONICATOR MM 1010) during 1 min to produce the oil-
in-water emulsion. The organic phase was evaporated during 20 min using a rotative evaporator 
under partial vacuum. The nanoparticles were recovered by ultracentrifugation (21,000 rpm, 25 
min, Hitachi). Then collect and accurately weighed 50 mg of Glibenclamide was used sprinkled 
directly to surface of the dissolution medium. And dissolution studies were carried out 
withTYPE II (LABINDIA, DISSO 2000) dissolution apparatus at a stirring speed of 100 rpm 
and 0.2 M hydrochloric acid at (pH 1.2) 37 ± 0.5°C as the dissolution medium. 
Anti solvent method
100 
Glibenclamidenanoparticles were prepared by the precipitation technique which is also 
called Anti solvent precipitation method. Glibenclamide  was dissolved in 3ml of Methanol, 
Ethanol and Acetone .Were  prepared by separately at room temperature this was poured  into 
10ml  water containing surfactants  ( Span 80) maintained at a temperature of 500C and 
subsequently  stirred at agitation speed of 250revolution per minute (rpm) on magnetic stirrer 
for1 hour to allow  the volatile  solvent to evaporate. Addition of organic solvents by means of 
syringe drop by drop positioned with the needle directly into surfactant containing water. Then 
collect and accurately weighed 50 mg of Glibenclamide was used sprinkled directly to surface of 
the dissolution medium. And dissolution studies were carried out with   TYPEII 
(LABINDIA,DISSO 2000) dissolution apparatus at a stirring speed of 100 rpm and 0.2 M 
hydrochloric acid at (pH 1.2) 37 ± 0.5°C as the dissolution medium. 
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IN- VITRO RELEASE STUDIES
101 
IN-VITRO dissolution studies of all formulations were carried out using 900 ml of 0.2 M 
hydrochloric acid at (pH 1.2 ) 37 ± 0.5°C as the dissolution medium in a Type IIapparatus 
(LABINDIA,DISSO 2000)  at a stirring speed of 100 rpm. Accurately weighed 
pureGlibenclamide solid dispersions and nanoparticles containing 50 mg of GB was used 
sprinkled directly to surface of the dissolution medium. Five  milliliter sample solution of 
dissolution medium were withdrawn at the   time interval 10,20,30,40,50and 60min and 
immediately replaced with an equal volume of the dissolution medium (maintained at  37 ± 
0.5°C) in order to maintain constant volume of dissolution medium. The withdrawn samples 
were filtered and analyzed for drug content at 302 nm and cumulative percentage of drug 
dissolved was calculated. The amount of drug removed in each sample was compensated in the 
calculations. All experiments were performed in triplicate. Drug release kinetics was also 
determined for Different kinetic models (zero-order and first-order). 
Kinetic analysis of dissolution data 
Drug release kinetic mechanism: 
To analyze the mechanism of drug release form the formulation, the dissolution profile of 
all the batches were fitted to zero order and first order to ascertain the kinetic modeling of drug 
release. 
Zero order: 
In many of the modified release dosage form particularly controlled or sustained release 
dosage form (those dosage forms that release the drug in planned, predictable and slower than 
normal manner) is zero order kinetics. 
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                                  Q=K0t 
Were, Q is the amount of drug release at time, t and K0 is the release constant. 
First Order: 
The dissolution data was fitted to first order equation 
                         In(100-Q) =In100=k1t 
Were k1 is the release rate constant 
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Chromatographic Study
102
 
Thin layer chromatographic method was used to study whether there was any interaction 
between Glibenclamide and carriers used for formulations, the test solution were prepared by 
dissolving all test formulation in Methanol and standard solution was prepared from pure 
Glibenclamide in same solvent. The TLC plates were prepared by spreading silica Gel G on dry 
glass plate in thin layer as stationary phase. The plats were activated at 1100c for one hour.10µl 
of each of the test solution were applied separately to theplats usingmicropipette. The spots were 
allowed to dry and chromatogram was developed using solvent system consisting of65:6:12:30 
Benzene: Acetic acid: Ethyl acetate: Acetone or 9:9:1:1 Chloroform:Cyclohexane:ethanol: 
Acetic acid as mobile phase. 
The plate was removed from developing chamber and solvent front was marked. The solvent was 
evaporated by drying in hot air oven and spots were detected in iodine chamber. The spots 
obtained with all the test solution and their Rf values were compared with standard solution. 
TheRf value was calculated by the following formula. 
 
Rf value =   Distance traveled by solute 
 Distance traveled by solvent 
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Estimation of Drug Content
93 
The drug contents in solid dispersion and nanoparticles were determined by the UV-
spectroscopic method. An accurately weighed quantity of solid dispersion and nanoparticles 
equivalent to 5 mg of GBM was transferred to a 100 ml volumetric flask containing 100 ml of 
methanol and dissolved. The solution was then filtered through the filter paper. 1 ml of this 
solution was diluted 10 times with 0.2 M HCL buffer solutions and the absorbance was measured 
at 302 nm. 
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I.R. Studies
103 
To know about the interaction between the drug and carriers used in the formulation, the 
IR analysis was carried out. The IR spectra of pure Glibenclamide, solid dispersions ratio of 1:1 
and nanoparticles was studied by FTIR It is scanned over the Frequency range of 4000-500 cm
-1 
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XRD Studies
104 
TheXRD studies for analyzing structural nature of Glibenclamide, solid dispersion and 
nanoparticle formulation of Glibenclamide. The samples were placed in sample cell and spread 
evenly. The sample cell was placed in X-ray Diffractometer (BRUKER ECO D8). The samples 
were scanned over the frequency range of 10-80. 
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PARTICLE SIZE ANALYSIS OF SOLID DISPERSION
105
 
An ordinary compound microscope was used for this purpose. The ordinary microscope 
is used for the measurement of particle size in the range of 0.2 to 100 µm. Test material, diluted 
or undiluted is mounted on a slide and placed on a mechanical stage. The eyepiece of the 
microscope is fitted with a micrometer, using which the sizes of particles are determined. 
Eyepiece micrometer should be calibrated using a standard stage micrometer. In this, one 
millimeter is divided into 100 equal divisions and hence, each division is equal to 10 µm. The 
eyepiece micrometer, which is linear, consists of 100 divisions. Calibration is undertaken to find 
out the measure of each division. 
Procedure: 
A small amount of prepared solid dispersions of physical mixture, dropping, solvent 
evaporation and wet grinding formulations were diluted with petroleum ether. A few drops of 
this suspension were transferred onto a glass slide and focused in a microscope. The number of 
division of eyepiece micrometer determined the diameters of 300 particles randomly. This is then 
converted in to microns and then average particle size was determined. 
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PARTICLE SIZE ANALYSIS OF NANOPARTICLES: 
The prepared Nanoparticles size can be analysed, by using Malvern size analyzer. In 
this analytical method the samples were dispersed in water and placed in a sample cell 
(Disposable sizing cuvette). Then the cuvette were placed in analyzer we set the measurement 
position(mm). The analyzer can be run and analyze the particle size distribution of sample and 
average particle size of samples (diameter in nanometric range). Size distribution can be 
determined by plotting a graph by intensity (Percent) vs. size (d.nm) 
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STABILITY STUDIES
105: 
To evaluate the stability of drug, Glibenclamide, and the effect of carriers after storing at 
different Temperature and Relative Humidity for 30 days stability studies were carried out  
About 100mg of equivalent of Glibenclamide formulations were taken in well closed containers 
from ideal batches and stored separately at 40
0
C+ 2
0
C/75% RH + 6% (Accelerated testing) and 
300C+ 20C/60% RH + 5% (Alternate testing). From these, sample equivalent to 20 mg of 
Glibenclamide was removed at the interval if 10, 20, 30 days and analyzed the drug content by 
spectrophotometrically at 302 nm.   
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RESULTS AND DISCUSSIONS 
Table No:8.1 
Formulation code  
SI.NO Method of preparation 
(DRUG:CARRIER:METHOD:RATIO) 
FORMULATION 
CODE 
1 Pure Glibenclamide GB 
2 GlibenclamidePeg600 physical mixture 1:1 GPP1 
3 GlibenclamidePeg600 physical mixture 1:2 GPP1 
4 GlibenclamidePeg600 physical mixture 1:3 GPP1 
5 GlibenclamidePeg600 dropping method 1:1 GPD1 
6 GlibenclamidePeg600 dropping method 1:2 GPD1 
7 GlibenclamidePeg600 dropping method 1:3 GPD1 
8 GlibenclamidePeg600 solvent evaporation 1:1 GPS1 
9 GlibenclamidePeg600 solvent evaporation  1:2 GPS1 
10 GlibenclamidePeg600 solvent evaporation  1:3 GPS1 
11 Glibenclamide Urea physical mixture 1:1 GUP1 
12 GlibenclamideUrea physical mixture 1:2 GUP1 
13 GlibenclamideUrea physical mixture 1:3 GUP1 
14 GlibenclamideUrea dropping method 1:1 GUD1 
15 GlibenclamideUrea dropping method 1:2 GUD1 
16 GlibenclamideUrea dropping method 1:3 GUD1 
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17 GlibenclamideUrea solvent evaporation 1:1 GUS1 
18 GlibenclamideUrea solvent evaporation 1:2 GUS1 
19 GlibenclamideUrea solvent evaporation 1:3 GUS1 
20 Glibenclamide Chitosan physical mixture 1:1 GCP1 
21 Glibenclamide Chitosan physical mixture 1:2 GCP1 
22 Glibenclamide Chitosan physical mixture 1:3 GCP1 
23 Glibenclamide Chitosan wet grinding 1:1 GCW1 
24 Glibenclamide Chitosan wet grinding 1:2 GCW1 
25 Glibenclamide Chitosan wet grinding 1:3 GCW1 
26 Glibenclamide Methanol spane 80 nanoparticles GMSN1 
27 Glibenclamide Ethanol spane 80 nanoparticles GESN2 
28 Glibenclamide Acetone spane 80 nanoparticles GASN3 
29 Glibenclamide sonicated nanoparticles GSN 
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Screening of Carriers: 
For the screening study, the carriers PEG 6000,β-Cyclodextrin, Urea, Chitosan and PVP 
K30 were used to prepare solid dispersion of Glibenclamide; only PEG 6000, Urea and Chitosan 
were used to prepare solid dispersions. The observations of the screening study are shown 
inTableNo:8.2from the screening studies, it was possible to prepare the solid dispersion system 
of Glibenclamide by solvent evaporation and dropping method withPEG6000 and Urea. 
Wet grinding method Chitosanand PEG6000, Ureaand Chitosan by physical mixing method 
TableNo:8.2 
Screening of Carriers (Drug:Polymer = 100mg: 100mg) 
 
Carrier 
 
Miscible/Immiscible 
 
Discoloration 
 
Final 
texture 
 
Final 
color 
 
yield 
 
PEG600 
 
Miscible 
 
__ 
 
Crystalline 
Solid 
 
White 
 
182mg 
 
Urea 
 
Miscible 
 
__ 
 
Crystalline 
Glassy 
solid 
 
White 
 
178mg 
 
Chitosan 
 
Miscible 
 
__ 
 
Fine Solid 
 
Pale 
Yellow 
 
187mg 
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Effect of Carriers on Solubility of Glibenclamide  
To find out the effect of carriers on solubility of pure drug (Glibenclamide), solubility 
study was carried out using 1:1solid dispersion and nanoparticle of drug formulations in distilled 
water. The results are shown in TableNo:8.3 
TableNo:8.3 
Effect of Carriers on Solubility of Glibenclamide 
S.No Formulation Code Solubility µg/ml 
 
1. 
 
GB 
 
.335 
 
2. 
 
GPP1 
 
1.68 
 
3. 
 
GUP1 
 
2.01 
 
4. 
 
GCP1 
 
1.81 
 
5. 
 
GMSN1 
 
.673 
 
6. 
 
GESN2 
 
.773 
 
7. 
 
GASN3 
 
.893 
 
8. 
 
GSN1 
 
.542 
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Estimation of drug content: 
All the Solid dispersions and nanoparticles were extracted with Methanol and the extract 
was suitably diluted with 0.2 M Hcl buffer pH 1.2. The Glibenclamide content was estimated 
spectrophotometrically 302 nm. 
The formulation PEG600 physical mixing:(GPP1) 95.9%, (GPP2)97.8 and (GPP3)98.2,  
The formulation PEG600dropping method: (GPD1)97, (GPD1) 97.6 and (GPD3)98.6, The 
formulation PEG600 solvent evaporation method: (GPS1)97.4, (GPS2)95.6 and (GPS3)96.4, The 
formulation UREA physical mixing:(GUP1)97.4, (GUP2)96.6 and (GUP3)98.4.   The 
formulation UREAdropping method:(GUD1)97, (GUD2)97.2 and (GUD3)98.2 The formulation 
UREA solvent evaporation method:(GUS1)97.6, (GUS2)97.6 and (GUS3)98.6, The formulation 
CHITOSAN physical mixing:(GCP1)95.2, (GCP2)95.8 and (GCP3)96.6, formulation 
CHITOSAN Wet grinding :(GCW1)97.2, (GCW2)98.4 and (GCW3)98, The nanoparticle 
formulations: (GMSN1) 98.6, (GESN2)98, (GASN3)98.4 and (GSN)98.6. The results are 
presented inTableNo: 8.4. The results showed that the percentage of Glibenclamide was ranging 
from 95-98% in all formulations itrevealsthat the drug, in all dispersed and conforms 
homogeneous mixing of drug and carriers. However slight variation of Glibenclamide may be 
due to physically loss of drug and instrumental or handling error. 
 
 
 
 
 
AKCP DEPARTMENT OF PHARMACEUTICS  Page | 69 
 
 
TableNo8.4 
Estimation of drug content 
S.No Drug :carrier  ratio and Formulation code % Glibenclamide 
1  1:1PEG 6000  (GPP1)  95.9 
2 1:2PEG 6000  (GPP2) 97.8 
3 1:3PEG 6000  (GPP3) 98.2 
4 1:1PEG 6000  (GPD1) 97 
5 1:2PEG 6000  (GPD2) 97.6 
6 1:3PEG 6000  (GPD3) 98.6 
7 1:1PEG 6000  (GPS1) 97.4 
8 1:2PEG 6000  (GPS2) 95.6 
9 1:3PEG 6000  (GPS3) 96.4 
10 1:1 UREA       (GUP1) 97.4 
11 1:2 UREA       (GUP2) 96.6 
12 1:3 UREA       (GUP3) 98.4 
13 1:1 UREA       (GUD1) 97 
14 1:2 UREA       (GUD2) 97.2 
15 1:3 UREA       (GUD3) 98.2 
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S.No Drug :carrier  ratio and Formulation code % Glibenclamide 
16 1:1 UREA       (GUS1) 97.6 
17 1:2 UREA       (GUS2) 97.6 
18 1:3 UREA       (GUS3) 98.6 
19 1:1 CHITOSAN  (GCP1) 95.2 
20 1:2 CHITOSAN  (GCP2) 95.8 
21 1:3 CHITOSAN  (GCP3) 96.6 
22 1:1 CHITOSAN  (GCW1) 97.2 
23 1:2 CHITOSAN  (GCW2) 98.4 
24 1:3 CHITOSAN  (GCW3) 98 
25 GMSN1 98.6 
26 GESN2 98 
27 GASN3 98.4 
28 GSN 98.6 
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IN-VITRO RELEAESTUDIES: 
The ultimate aim of this work was to develop a suitable formulation for Glibenclamide 
.which can dissolve maximum amount of drug in 1 hour .Hence, different batches of solid 
dispersions and nanoparticles were studied for in-vitro dissolution. The results are shown in 
TablesNo:8.5, 8.6, 8.8, 8.10,8.12, 8.14, 8.16, 8.18, 8.20, 8.22   The results are also plotted in the 
form of % drug release Vs time as shown in Figures:8.1, 8.2, 8.5, 8.8, 8.11, 8.14, 8.17, 8.20, 
8.23, and 8.26 
In the batches of solid dispersions prepared(Physical mixture) with PEG6000, the 
maximum dissolution of Glibenclamide, at the end of 1 hour, was observed with  1:3 
combination  of Physical mixture .At the end of 1 hour, this combination was able to release 
26.88% of drug. The least dissolution of Glibenclamide was observed with 1:1 combination, 
which able to release only 25.01% of Glibenclamide .Whereas, the other combination s 1:2 has 
released 26.1% of drug after 1hr. 
In the batches of solid dispersions prepared(Dropping method) with PEG6000, the 
maximum dissolution of Glibenclamide, at the end of 1 hour, was observed with  1:3 
combination  of dropping solid dispersions .At the end of 1 hour, this combination was able to 
release 29.59% of drug. The least dissolution of Glibenclamide was observed with 1:1 
combination, which able to release only 28.01% of Glibenclamide .Whereas, the other 
combinations 1:2 has released 28.83% of drug after 1hr. 
In the batches of solid dispersions prepared(Solvent evaporation) with PEG6000, the 
maximum dissolution of Glibenclamide, at the end of 1 hour, was observed with  1:3 
combination  of Solvent evaporated solid dispersions  .At the end of 1 hour, this combination 
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was able to release 38.81% of drug. The least dissolution of Glibenclamide was observed with 
1:1 combinations, which able to release only 31.60% of Glibenclamide .Whereas, the other 
combination s 1:2 havereleased 35.43% of drug after 1hr. 
Solid dispersion prepared by solvent evaporation method showed more release then 
physical mixture and dropping Solid dispersions of Glibenclamide with PEG6000. 
In the batches of solid dispersions prepared(Physical mixture) with Urea, the maximum 
dissolution of Glibenclamide, at the end of 1 hour, was observed with  1:3 combination  of 
Physical mixture .At the end of 1 hour, this combination was able to release 42.52% of drug. The 
least dissolution of Glibenclamide was observed with 1:1 combinations, which able to release 
only 38.13% of Glibenclamide .Whereas, the other combination s 1:2 have released 40.50% of 
drug after 1hr. 
In the batches of solid dispersions prepared(Dropping method) with Urea, the 
maximum dissolution of Glibenclamide, at the end of 1 hour, was observed with  1:3 
combination  of dropping solid dispersions .At the end of 1 hour, this combination was able to 
release 44.44% of drug. The least dissolution of Glibenclamide was observed with 1:1 
combinations, which able to release only 40.56% of Glibenclamide .Whereas, the other 
combination s 1:2 have released 43.87% of drug after 1hr. 
In the batches of solid dispersions prepared(Solvent evaporation) with Urea, the 
maximum dissolution of Glibenclamide, at the end of 1 hour, was observed with  1:3 
combination  of Solvent evaporated solid dispersions  .At the end of 1 hour, this combination 
was able to release 60.05% of drug. The least dissolution of Glibenclamide was observed with 
1:1 combinations, which able to release only 47.82% of Glibenclamide .Whereas, the other 
combination s 1:2 have released 54.78% of drug after 1hr. 
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Solid dispersion prepared by solvent evaporation method showed more release then physical 
mixture and dropping Solid dispersions of Glibenclamide with Urea. 
In the batches of solid dispersions prepared(Physical mixture) with Chitosan, the 
maximum dissolution of Glibenclamide, at the end of 1 hour, was observed with  1:3 
combination  of Physical mixture .At the end of 1 hour, this combination was able to release 
31.50% of drug. The least dissolution of Glibenclamide was observed with 1:1 combination, 
which able to release only 23.63% of Glibenclamide .Whereas, the other combination s 1:2 has 
released 28.01%of drug after 1hr. 
In the batches of solid dispersions prepared(Wet grinding  method) with Chitosan, the 
maximum dissolution of Glibenclamide, at the end of 1 hour, was observed with  1:3 
combination  of Solvent evaporated solid dispersions  .At the end of 1 hour, this combination 
was able to release 43.87% of drug. The least dissolution of Glibenclamide was  observed with 
1:1 combination, which able to release  only 30.94% of Glibenclamide .Whereas ,the other 
combination s 1:2  have released 37.12% of  drug  after 1hr. Solid dispersion prepared by Wet 
grinding  method showed more release then physical mixture  of Glibenclamide with Chitosan. 
Theof nanoparticles were prepared by Anti solvent method with Methanol was used as solvent 
(GMSN1) the maximum dissolution of Glibenclamide, at the end of 1 hour, was observed 
30.15% of Glibenclamide. 
The batches of nanoparticles were prepared by Anti solvent method with Ethanol was 
used as solvent (GMSN1) the maximum dissolution of Glibenclamide, at the end of 1 hour, was 
observed 31.50% of Glibenclamide.  
The nanoparticles were prepared by Anti solvent method with Acetone was used as solvent 
(GASN1) the maximum dissolution of Glibenclamide, at the end of 1 hour, was observed 
32.06% of Glibenclamide. 
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The nanoparticles were prepared by Sonication method (GSN) the maximum dissolution 
of Glibenclamide, at end of 1 hour, was observed 29.70% of Glibenclamide. 
In comparison of prepared   nanoparticles are improve release of pure Glibenclamide. 
And nanoparticles prepared by anti solvent   method showed more release then Sonicated 
nanoparticles. And GASN3 showed more release then GMSN1&GESN2 of Glibenclamide. 
The in vitro release was fitted to the various kinetic models.The drug release kinetics 
showed that the release was followed first order. Zero order and First order R2values was shown 
at TableNo:8.8, 8.9, 8.11, 8.13, 8.15, 8.17, 8.19, 8.21 and 8.23.Zero order and First order 
R2values are plotted in graph the Figure was shown 8.3, 8.4, 8.6, 8.7, 8.9, 8.10, 8.12, 8.13, 8.15, 
8.16, 8.18, 8.19, 8.20, 8.21, 8.22, 8.24, 8.25, 8.27 and 8.28. 
Comparison of Dissolution of Pure Drug with Solid dispersions and nanoparticles  
At the end of 60 minutes, the pure drug showed only6.64% dissolution,(TableNo: 8.5-
8.23 ,Figure 8.1-8.28) whereas , the solid dispersions of  physical  mixture, dropping and solvent 
evaporation method have achieved  release up to 26.88% , 29.59% and 38.81% (with 
PEG6000,)42.52%,44.44% and 60.05%(with Urea), and solid dispersions of  physical  mixture 
and wet grinding method have achieved  release up to 31.50% and 43.87% (with Chitosan).Then 
nanoparticles are achieved released  up to 30.15%(GMSN1),31.50%(GESN2),32.06%(GASN3) 
and 29.70%(GSN).It was  observed that solid dispersion of  drug with Urea showed highest 
dissolution followed by PEG6000 and Chitosan solid dispersion by solvent evaporation method. 
Physical mixture, dropping method and nanoparticles also improved the dissolution of 
Glibenclamide .but it was less compared to solid dispersion by solvent evaporation method. 
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TableNo:8.5 
In-Vitro Release of pure Glibenclamide 
 
 
 
 
 
 
 
 
 
Figure: 8.1 
 
Figure 8.1: Cumulative % drug Release vs. time plot pureGlibenclamide 
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TableNo:8.6 
In-Vitro Release of Glibenclamide Solid dispersion by physical mixture with 
PEG6000 
 
TableNo:8.7 
Release kinetic of Glibenclamide Solid dispersion by physical mixture with 
PEG6000 
 
 
 
Time  
(min) 
%Release of Glibenclamide 
1:1 1:2 1:3 
0 0 0 0 
10 6.45 6.98 6.64 
20 11.93 13.28 14.06 
30 18.23 19.03 19.80 
40 21.03 21.71 22.62 
50 24.21 24.75 25.53 
60 25.01 26.10 26.88 
Formulation code Zero order First order 
R
2 
R
2
 
GPP1 R² = 0.948 
 
R² = 0.961 
GPP2 R² = 0.944 R² = 0.960 
GPP3 R² = 0.939 R² = 0.955 
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Figure 8.2: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by physical mixture with PEG6000 
 
Figure 8.3: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by physical mixture with PEG6000 
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Figure 8.4: Log % remaining vs. Time plot Glibenclamide solid dispersion by 
physical mixture with PEG6000 
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Table No:8.8 
In-Vitro Release of Glibenclamide Solid dispersion by Dropping method 
withPEG6000 
 
TableNo:8.9 
Release kinetics of Glibenclamide Solid dispersion by Dropping method 
withPEG6000 
Formulation code Zero order First order 
R
2 
R
2
 
GPD1 R² = 0.920 R² = 0.938 
GPD2 R² = 0.947 R² = 0.965  
 
GPD3 R² = 0.930 R² = 0.952  
 
 
 
Time  
(min) 
%Release of Glibenclamide 
1:1 1:2 1:3 
0 0 0 0 
10             7.31 7.76 9.2 
20 14.85 15.41 16.76 
30            22.16 20.04 21.49 
40 23.63 23.85 24.41 
50 26.67 26.88 27.56 
             60            28.83 28..83 29.59 
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Figure 8.5: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by Dropping method with PEG6000 
 
Figure 8.6: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by Dropping method with PEG6000 
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Figure 8.7: Log % remaining vs. Time plot Glibenclamide solid dispersion by 
dropping method with PEG6000 
 
 
 
 
 
 
 
 
 
 
1.82
1.84
1.86
1.88
1.9
1.92
1.94
1.96
1.98
2
2.02
0 20 40 60 80L
o
g
 c
u
m
u
la
ti
v
e 
%
 R
em
a
in
in
g
Time(min)
First order
GPD1
GPD2
GPD3
AKCP DEPARTMENT OF PHARMACEUTICS  Page | 82 
 
 
TableNo:8.10 
In-Vitro Release of Glibenclamide Solid dispersion by Solvent evaporation 
with PEG6000 
 
TableNo:8.11 
Release kinetics of Glibenclamide Solid dispersion by Solvent evaporation 
with PEG6000 
 
 
 
 
 
 
 
 
 
 
 
  
 
Time 
(min) 
%Release of Glibenclamide 
1:1 1:2 1:3 
0 0 0 0 
10 10.91 13.38 14.06 
20 16.68 19.91 21.71 
30 23.67 26.1 28.23 
40 27.9 29.58 32.18 
50 30.71 34.76 36.33 
60 31.6 35.43 38.81 
Formulation code Zero order First order 
R
2 
R
2
 
GPS1 R² = 0.925 R² = 0.947 
GPS2 R² = 0.921 R² = 0.950 
GPS3 R² = 0.925 R² = 0.958  
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Figure 8.8: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by Solvent evaporationwith PEG6000 
 
 
Figure 8.9: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by Solvent evaporationwith PEG6000 
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Figure 8.10: Log % remaining vs. Time plot Glibenclamide solid dispersion by 
physical Solvent evaporationPEG6000 
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TableNo:8.12 
In-Vitro Release of Glibenclamide Solid dispersion by Physical mixing with 
UREA 
 
TableNo:8.13 
Release kinetics of Glibenclamide Solid dispersion by Physical mixing with 
UREA 
Formulation code Zero order First order 
R
2 
R
2
 
GUP1 R² = 0.944  
 
R² = 0.971  
 
GUP2 R² = 0.955 R² = 0.979 
GUP3 R² = 0.950 R² = 0.976 
 
 
Time  
(min) 
%Release of Glibenclamide 
1:1 1:2 1:3 
0 0   
10 14.18 14.4 15.64 
20 19.58 20.14 21.15 
30 25.54 26.44 27.34 
40 31.26 31.17 34.89 
50 36.45 38.25 40.56 
60 38.13 40.5 42.52 
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Figure 8.11: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by physical mixture with UREA 
 
 
Figure 8.12: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by physical mixture with UREA 
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Figure8.13: Log % remaining vs. Time plot Glibenclamide solid dispersion by 
physical mixture UREA 
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TableNo:8.14 
In-Vitro Release of Glibenclamide Solid dispersion by Dropping method with 
UREA 
 
TableNo:8.15 
Release kinetics of Glibenclamide Solid dispersion by Dropping method with 
UREA 
Formulation code Zero order First order 
R
2 
R
2
 
GUD1 R² = 0.944 R² = 0.974 
GUD2 R² = 0.952 R² = 0.979 
GUD3 R² = 0.943 R² = 0.974 
 
 
Time  
(min) 
%Release of Glibenclamide 
1:1 1:2 1:3 
0  0 0 
10 15.08 15.87 16.75 
20 21.27 22.62 23.29 
30 26.89 27.92 29.25 
40 31.95 34.32 36 
50 37.35 41.62 42.52 
60 40.56 43.87 44.44 
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Figure 8.14: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by Dropping method with UREA 
 
 
Figure 8.15: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by Dropping method with UREA 
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Figure 8.16: Log % remaining vs. Time plot Glibenclamide solid dispersion by 
physical Dropping method with UREA 
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Table No: 8.16 
In-Vitro Release of Glibenclamide Solid dispersion by Solvent evaporation 
with UREA 
 
TableNo:8.17 
Release kinetics of Glibenclamide Solid dispersion by Solvent evaporation 
with UREA 
Formulation code Zero order First order 
R
2 
R
2
 
GUS1 R² = 0.944 R² = 0.979 
GUS2 R² = 0.942 R² = 0.982  
 
GUS3 R² = 0.943 R² = 0.986  
 
Time  
(min) 
%Release of Glibenclamide 
1:1 1:2 1:3 
0 0 0 0 
10 18.22 20.92 22.84 
20 24.75 29.14 31.5 
30 31.5 35.32 39.15 
40 37.12 43.87 47.82 
50 44.44 50.85 56.59 
60 47.82 54.78 60.05 
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Figure 8.17: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by Solvent evaporation with UREA 
 
 
Figure 8.18: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by Solvent evaporation with UREA 
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Figure 8.19: Log % remaining vs. Time plot Glibenclamide solid dispersion by 
Solvent evaporation with UREA 
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TableNo:8.18 
In-Vitro Release of Glibenclamide Solid dispersion by Physical mixing with 
CHITOSAN 
 
Table No: 8.19 
Release kinetics of Glibenclamide Solid dispersion by Physical mixing with 
CHITOSAN 
 
 
 
 
 
Time  
(min) 
%Release of Glibenclamide 
1:1 1:2 1:3 
0 0 0 0 
10 10.28 13.61 15.41 
20 13.16 16.2 19.01 
30 15.3 19.13 21.71 
40 18.56 23.06 25.54 
50 21.38 25.54 29.03 
60 23.63 28.01 31.5 
Formulation code Zero order First order 
R
2 
R
2
 
GCP1 R² = 0.917 R² = 0.939 
GCP2 R² = 0.886 
 
R² = 0.904 
 
GCP3 R² = 0.878 R² = 0.914 
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Figure 8.20: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by physical mixture with CHITOSAN 
 
 
Figure 8.21: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by physical mixture method with CHITOSAN 
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Figure 8.22: Log % remaining vs. Time plot Glibenclamide solid dispersion by 
physical mixture CHITOSAN 
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TableNo:8.20 
In-Vitro Release of Glibenclamide Solid dispersion by wetgrinding with 
CHITOSAN 
 
TableNo:8.21 
 
Release kinetics of Glibenclamide Solid dispersion by wetgrinding with 
CHITOSAN 
 
 
 
 
 
 
Time  
(min) 
%Release of Glibenclamide 
1:1 1:2 1:3 
0 0 0 0 
10 12.94 13.39 14.96 
20 16.88 18.22 21.04 
30 20.48 24.41 27.56 
40 23.51 28.46 33.41 
50 27.79 33.75 39.26 
60 30.94 37.12 43.87 
 
Formulation code Zero order First order 
R
2 
R
2
 
GCW1 R² = 0.924 R² = 0.951 
GCW2 R² = 0.954 R² = 0.978 
GCW3 R² = 0.963  
 
R² = 0.987 
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Figure8.23: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by Wet grinding method with CHITOSAN 
 
Figure 8.24: Cumulative % drug Release vs. time plot Glibenclamide solid 
dispersion by Wet grinding method with CHITOSAN 
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Figure8.25: Log % remaining vs. Time plot Glibenclamide solid dispersion by Wet 
grinding CHITOSAN 
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TableNo:8.22 
In-Vitro Release of Glibenclamide by nanoparticles Formulations  
 
TableNo:8.23 
Release kinetics of Glibenclamide by nanoparticles Formulations 
Formulation code Zero order First order 
R
2 
R
2
 
GMSN1 R² = 0.931 R² = 0.950 
GESN2 R² = 0.941  
 
R² = 0.962 
GASN3 R² = 0.868 R² = 0.906 
GSN R² = 0.867 R² = 0.902 
 
 
Time  
(min) 
%Release of Glibenclamide 
GMSN1 GESN2 GASN3 GSN 
0 0 0 0 0 
10 13.5 12.94 15 14.85 
20 13.6 14.63 20.59 18.11 
30 18 20.81 22.95 21.1 
40 22.61 23.63 26.44 25.2 
50 28.13 28.91 29.26 27.34 
60 30.15 31.5 32.06 29.7 
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Figure 8.26: Cumulative % drug Release vs. time plot Glibenclamide by 
Nanoparticles formulations 
 
 
Figure 8.27: Cumulative % drug Release vs. time plot Glibenclamide by 
Nanoparticles formulations 
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Figure8.28: Log % remaining vs. Time plot Glibenclamide by Nanoparticles 
formulations 
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Chromatographic Study: 
Thin layer chromatography: 
The TLC studies of the ideal batches of solid dispersions, physical mixture and nanoparticles 
were carried out and calculated The TLC chromatography study is shown Rf value of pure 
Glibenclamide was (0.64), GPP3 (0.61), GUP3 (0.62) GCP3 (0.62) GSN (0.64), GMSN1 (0.63) 
GESN2 (0.64) GASN (0.64) the Rf value also nearby pure Glibenclamide so there is polymeric 
interaction may not take place in above formulations.Rf values are shown in TableNo: 8.24 
 
TableNo: 8.24 
Rf values ofGlibenclamide solid dispersion, physical mixture andnanoparticles. 
S.No Formulation Rf value 
1. Pure Glibenclamide(GB) 0.64 
2. GPP3 0.61 
3. GUP3 0.62 
4. GUP3 0.62 
5. GSN 0.64 
6. GMSN1 0.63 
7. GESN2 0.64 
8. GAS3 0.64 
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The Rf value of pure drug, soliddispersion and nanoparticles were nearly same indicating 
that the drug is not degraded in the solid dispersion and nanoparticles formulations. 
FTIR STUDY: 
The Infrared spectral analysis was carried out to the Study the Interaction between drug 
carriers. The IR spectrums as shown in Figures:8.29-8.36 
The FTIR spectra of pure Glibenclamide and formulations of solid dispersion ratio 1:1 
and nanoparticles were found to identical. The Absorption peak of  following functional group 
are shown within the rang like Amide group at 1680-1630 cm
-1
,Aromatic CH group at 3000-
2850cm
-1
Sulfonamide SO group at1050cm
-1
 and Halogen Cl group at 785-540
-1
. The above 
functional groups also present in the Glibenclamide. The IR spectrum of pure Glibenclamide, 
solid dispersion and nanoparticles of the formulations are shown peaks within the range of 
functional groups. This indicates that there was no chemical interaction or bonding or 
decomposition of Glibenclamide employed in the formulations and formulations with various 
carriers. 
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FIGURE 6.29: FTIR SPECTRUM OF PURE GLIBENCLAMIDE (GB) 
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FIGURE 6.30: FTIR SPECTRUM OF GLIBENCLAMIDE SOLID DISPERSION 
WITH PEG6000 (GPP1) 
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FIGURE 6.31: FTIR SPECTRUM OF GLIBENCLAMIDE SOLID DISPERSION 
WITH UREA (GUP1) 
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FIGURE 6.32: FTIR SPECTRUM OF GLIBENCLAMIDE SOLID DISPERSION 
WITH CHITOSAN (GCP1) 
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FIGURE 6.33: FTIR SPECTRUM OF GLIBENCLAMIDE NANOPARTICLES 
BY USING METHANOL 
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FIGURE 6.34: FTIR SPECTRUM OF GLIBENCLAMIDE NANOPARTICLES 
BY USING ETHANOL 
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FIGURE 6.35: FTIR SPECTRUM OF GLIBENCLAMIDE NANOPARTICLES 
BY USING ACETONE 
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FIGURE 6.36: FTIR SPECTRUM OF GLIBENCLAMIDE NANOPARTICLES 
BY ULTRASONICATION METHOD 
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XRD Studies: 
The XRD of pure Glibenclamide with various carriers of solid dispersion and 
nanoparticles were studied. The XRD spectrums are shown figure 8.37-8.44. In this study the 
crystalline nature of pure Glibenclamide was reduced in form of solid dispersion and 
Nanoparticles of Glibenclamide. 
In the study   a pure drugshowedmore   peak intensity the drug showed more crystalline 
nature. The solid dispersions of PEG600, Chitosan and Urea were showed less peak intensity 
compared to pure Glibenclamide .Its indicates the nature of crystalline property was decreased 
orit’sbecome amorphous form. The nanoparticles were showed less peak intensity of pure 
Glibenclamide But its less in solid dispersions .The solid dispersion of Urea were showed 
veryless peak intensity of other formulations of solid dispersion and nanoparticles. So the solid 
dispersion of Urea has been showed more soluble in other formulations.  
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FIGURE 8.37:XRD SPECTRUM OF PURE GLIBENCLAMIODE(GB) 
 
FIGURE 8.38: XRD SPECTRUM OF  GLIBENCLAMIODE SOLID 
DISPERSION WITH PEG6000(GPP1) 
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FIGURE 8.39: XRD SPECTRUM OF  GLIBENCLAMIODE SOLID 
DISPERSION WITH UREA(GUP1) 
 
FIGURE 8.40:XRD SPECTRUM OF  GLIBENCLAMIODE SOLID 
DISPERSION WITH CHITOSAN(GCP1) 
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FIGURE 8.41:XRD SPECTRUM OF  GLIBENCLAMIODE NANOPARTICLES 
WITH METHANOL(GMSN1) 
 FIGURE 8.42:XRD SPECTRUM OF  GLIBENCLAMIODE 
NANOPARTICLES WITH ETHANOL(GESN2) 
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FIGURE 8.43:XRD SPECTRUM OF  GLIBENCLAMIODE NANOPARTICLES 
WITH ACETONE(GASN3) 
FIGURE 8.44: XRD SPECTRUM OF  GLIBENCLAMIODE 
NANOPARTICLES BY ULTRASONICATION METHHOD 
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Particle Size Analysis: Solid dispersion  
 Particle size of best releasing formulations were analyzed by using compound 
microscope the obtained values can be followed: GPP3 (165.64µ), GPD3 (179.53µ), GPS3 
(143.89µ), GUP3 (158.42µ), GUD3 (164.56µ), GUS3 (139.82µ), GCP3 (162.93µ), GCW3 
(178.34µ). 
Results are shown inTableNo: 8.25 
Table No: 8.25 
Particle size if Ideal Batches of best releasing solid dispersion formulations 
Formulations Average particle size(µ) 
GPP3 165.64 
GPD3 179.53 
GPS3 143.89 
GUP3 158.42 
GUD3 164.56 
GUS3 139.82 
GCP3 162.93 
GCW3 178.34 
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Particle Size Analysis: nanoparticles  
Particle size of best releasing formulations were analyzed by using MALVERN particle 
sizeAnalyzer the results can be followed: GMSN1 {225.5(d.nm)}, GESN2 {28.20(d.nm)}, 
GASN3 {1076 and 283.7 (d.nm)} and GSN {141.8 (d.nm)}. 
Were, 
d.nm is diameter in nanometer.  
The results are shown inTable No: 8.26 
Table No: 8.26 
Particle size if Ideal Batches of best releasing nanoparticle formulations 
 
Formulations Average particle size(d.nm) 
GMSN1 225.5 
GESN2 28.20 
GASN3 1076 
283.7 
GSN 141.8 
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Particle size if Ideal Batches of best releasing nanoparticle formulations 
Figure 8.45: 
 
Figure 8.46: 
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Figure 8.47: 
 
Figure 8.48: 
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Preparation and characterization of tablets: 
 
Glibenclamide solid dispersions in GUS3 formulatedinto tablets. The tablets containing 
5mg of Glibenclamide were prepared by directcompression method as per the formula given in 
the table. Theprepared tablets were stored in screw capped glass bottles. Theprepared tablets 
were evaluated for drug release characteristics 
Table No: 8.27 
Si No Ingredients Formulations (mg) 
GB GUS3 
1 Glibenclamide 5 - 
2 Glibenclamide-Urea solvent evaporated (1:3) - 5 
3 Lactose 25 25 
4 Micro crystalline cellulose 157.5 157.5 
5 Talc 5 5 
6 Magnesium stearates 5 5 
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Evaluation of tablets 
Tablet formulations are evaluated for the following  
Weight variation test 
Individual weight of 20 tablets was taken and the average weight was calculated by using 
following formula. 
 
(Weight of tablet- Average weight) 
  Weight variation=   ------------------------------------------- x 100 
                                             Average weight of tablet 
 
 
Weight variation should not be more than 5.5%. 
Friability 
Friability of the tablets was calculated by the use of friabilator. Friability should be less than 1. 
Disintegration time 
 Disintegration time of the tablet was observed with the help of Disintegration apparatus. 
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Physical parameter studies 
Table No: 8.28 Physical parameter studies of different tablet formulations 
Parameter GB GUS3 
Thickness (mm) 3.2 3.4 
Hardness (kg/cm
3
) 2.6 2.5 
Disintegrating time(min) 1-4 1-3 
Friability in (in %) 0.421 0.396 
Weight Variation  
S.no Wt (mg) Wt (mg) 
1 ૛૚૙.૛ 212 
2 ૛૚૛.ૡ 210.4 
3 ૛૚૜ 211 
4 ૛૚૛.૞ 214 
5 ૛૚૛.ૡ 212.3 
6 ૛૚૜.૝ 212.5 
7 ૛૚૝.ૠ 213 
8 ૛૚૚.ૡ 210.8 
9 ૛૚૟.૜ 211.2 
10 ૛૚૛.ૡ 213.2 
11 ૛૚૜.ૢ 211.5 
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The results in table No: 8.28 indicates that tablets are within the limits 
 
 
 
 
 
 
 
 
12 ૛૚૛.૟ 214 
13 ૛૚૝ 212.6 
14 ૛૚૜.૝ 212.6 
15 ૛૚૛.૞ 213 
16 ૛૚૚.૜ 212.1 
17 ૛૚૙ 212.4 
18 ૛૚૝.૛ 213 
19 ૛૚૝ 212.4 
20 ૛૚૞ 213.6 
Average 213.6 212.38 
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TableNo:8.29 
Dissolution of Glibenclamide from tablet formulations 
 
 
 
 
 
 
 
 
 
 
 
 
In this study the best release solid dispersion and pure Glibenclamide was converted in to 
tablet form and it wascompared to marketed available same dose of Glibenclamide the result 
shows the 81.83% of drug release. So the solid dispersion formulation was better than marketed 
available formulation. 
 
Time 
(min) 
Percentage of Glibenclamide dissolved 
GB 
TABLET 
GUS3 TABLET MARKETED 
TABLET 
0 0 0 0 
10 3.67 12.67 12.79 
20 7.82 28.19 27.43 
30 11.46 41.43 40.21 
40 14.87 55.74 51.46 
50 17.64 69.30 65.67 
60 20.76 81.83 76.82 
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STABILITY STUDIES 
Formulations were stored at400C+ 20C/75% RH + 6% (Accelerated testing) and 300C+ 
20C/60% RH + 5% (Alternate testing).After 30 days of storage,the formulations were observed 
physically and no colorchanges occurred. The content of Glibenclamide in all best formulations 
at various intervals of 10, 20, and 30 days was calculated. The result proved that the percentage 
of Glibenclamide was not less than 2-3 % in all best formulationsas shown in TableNo: 8.30. 
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TableNo: 8.30 
Stability Analysis of ideal formulations 
Formula
tion 
code 
Temperature(oC) % of Glibenclamide 
0 
Days 
10 
Days 
20 
Days 
30 
Days 
GB 400C+ 20C/75% RH + 6% 98.98 98.94 98.96 98.76 
30
0
C+ 2
0
C/60% RH + 5% 98.98 98.99 98.96 98.97 
GPP3 400C+ 20C/75% RH + 6% 98.20 98.23 98.21 98.22 
300C+ 20C/60% RH + 5% 98.20 98.19 98.24 98.21 
GPD3 40
0
C+ 2
0
C/75% RH + 6% 98.60 98.58 98.63 98.62 
300C+ 20C/60% RH + 5% 98.60 98.65 98.64 98.58 
GPS3 40
0
C+ 2
0
C/75% RH + 6% 96.40 96.48 96.44 96.38 
30
0
C+ 2
0
C/60% RH + 5% 96.40 96.42 96,47 96.47 
GUP3 400C+ 20C/75% RH + 6% 98.40 98.39 98.43 98.37 
30
0
C+ 2
0
C/60% RH + 5% 98.40 98.42 98.42 98.39 
GUD2 400C+ 20C/75% RH + 6% 98.20 98.30 98.17 98.24 
300C+ 20C/60% RH + 5% 98.20 98.19 98.13 98.24 
GUS3 40
0
C+ 2
0
C/75% RH + 6% 98.60 98.69 98.57 98.63 
300C+ 20C/60% RH + 5%  98.60 98.62 98.58 98.64 
GCP3 400C+ 20C/75% RH + 6% 96.60 96.89 96.80 96.79 
30
0
C+ 2
0
C/60% RH + 5% 96.60 96.73 96.79 96.58 
GCW3 400C+ 20C/75% RH + 6% 98.00 98.12 98.02 97.97 
300C+ 20C/60% RH + 5% 98.00 98.16 98.09 98.03 
GASN3 40
0
C+ 2
0
C/75% RH + 6% 98.40 98.35 98,42 98.48 
300C+ 20C/60% RH + 5% 98.40 98.42 98.42 98.42 
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SUMMARY 
Solid dispersion technology is the science of dispersing one or more active ingredients in 
an inert matrix in solid state in order to achieve increasing dissolution rate, to sustain in the 
release of drugs, to alter solid state properties and to improve and enhance the release of drugs 
from ointment and suppository bases and improve the solubility and stability. Nanotechnology is 
a technique to decreases the particle size of materials. Whether increases specific surface area of 
a drug subsequently to increases the absorption of drug from site of administration. 
The study was performed in the following phases, 
All the above phases of investigation brought out several factors, which lead to following 
conclusions. 
1. Preliminary investigation of the effect of carriers in the solubility of Glibenclamide, various 
formulation methods can be followed as like physical mixture, dropping, solvent evaporation 
and wet grinding of Glibenclamide with suitable carriers.The nanoparticles were prepared by 
ultra Sonication and anti solvent method. 
2. Studies on drug – polymer interactionby using FTIR and TLC chromatography study in FTIR 
spectral analysis shows there are no interaction of pure Glibenclamide spectrum. The solid 
dispersion and nanoparticles spectrum are same like pure Glibenclamide spectrum. The TLC 
chromatography study is shown Rf value of pure Glibenclamide was(0.64), GPP3 (0.61), 
GUP3 (0.62) GCP3 (0.62) GSN (0.64), GMSN1 (0.63) GESN2 (0.64) GASN (0.64) the Rf 
value also nearby pure Glibenclamide so there is polymericinteraction may not take placein 
above formulations. 
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3. Study about nature of drug;  in the study   the pure drugshowed more   peak intensity.The drug 
showed more crystalline nature. The solid dispersions of PEG6000, Chitosan and Urea were 
showed less peak intensity compared to pure Glibenclamide. It indicates the nature of 
crystalline property was decreased or its converts to amorphous form. The nanoparticles were 
showed less peak intensity of pure Glibenclamide But its more than in solid dispersions .The 
solid dispersion of Urea were showed veryless peak intensity of other formulations of solid 
dispersion and nanoparticles. So we are concluded the solid dispersion of Urea have been 
more soluble in compared to other formulations.  
4. Study about particle size.The prepared solid dispersion formulations were studied under the by 
microscopy method by usingcompound microscopy the obtained values can be followed: 
GPP3 (165.64µ), GPD3 (179.53µ), GPS3 (143.89µ), GUP3 (158.42µ), GUD3 (164.56µ), 
GUS3 (139.82µ), GCP3 (162.93µ), GCW3 (178.34µ). Particle size of best releasing 
formulations were analyzed by using MALVERN particle size Analyzer obtained values can 
be followed: GMSN1 {225.5(d.nm)}, GESN2 {28.20(d.nm)}, GASN3 {1076 and 283.7 
(d.nm)} and GSN {141.8 (d.nm)}.were d.nm is diameter in nanometer. 
5. Solubility study.The water soluble carriers can be in solid dispersion techniquesignificance 
increases in the solubility of Glibenclamide. Among these carriers urea was found to possess 
highest solubilizing characters and dissolutions in solvent evaporation method of 
preparation.All the Glibenclamide nanoparticles were found to increases the solubility of 
Glibenclamide significantly, but lesser then solid dispersion of Glibenclamide. 
6. Dissolution study. The dissolution rate of pure drug was compared with various solid 
dispersions at different ratios of all the polymers showed significant increases in the rate of 
dissolution in solid dispersion and nanoparticles. The dissolution rate of urea was greater 
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than the other polymeric and nanoparticle formulations because the rate of dissolution of 
solid dispersion urea was 60.05%, while pure drug showed only 6.64% dissolution rate at the 
end of 60 minutes. 
Dissolution profile of drugformulation produced by different methods is 
compared: 
The dissolution profile of solvent evaporation method was more than wet grinding. Wet 
grinding method was comparable to greater than dropping method and lesser then solvent 
evaporation method.Thedropping method was comparable to greater thanPhysical mixture and 
lesser thansolvent evaporation method,wet grinding method.Physical mixture was comparable to 
lesser then Solvent evaporation,wet grinding and Dropping method. The decreasing order of 
Dissolution profile of drug formulation is followed. 
Solvent evaporation > Wet grinding> Dropping method> Physical mixture 
7. Stability studies of prepared best formulations 
      Drug degradation was tested after storing ideal batches of solid dispersion and nanoparticles 
different temperature and Relative humidityat 400C+ 20C/75% RH + 6% (Accelerated 
testing) and 30
0
C+ 2
0
C/60% RH + 5% (Alternate testing). There was no degradation of drug 
after storing for 30 days at only 2-3% of drug was degraded after 30 days. 
8. Comparison of marketed available drug: 
 In this study the best release solid dispersion and pure Glibenclamide was converted in to 
tablet form and its compared to marketed available same dose of Glibenclamide the result 
shows the  release of solid dispersion  better than  marketed available drug 
 
 
AKCP DEPARTMENT OF PHARMACEUTICS  Page | 132 
 
 
CONCLUSION 
Form the present research work, it is concluded that the preparation of solid dispersion of 
poorly soluble drugs like Glibenclamide with suitable carriers like PEG 6000, UREA, 
CHITOSAN, and Nanoparticles to enhance the dissolution rate. The robust formulation in solid 
dispersion is with solvent evaporation by urea shows higher in-vitro dissolution rate. 
The dissolution characteristics of Glibenclamide were improved by formulation of solid 
dispersion with PEG 6000, UREA, CHITOSAN and Nanoparticles in decreases in the 
crystallinity of the drug substance is decisive for the increases dissolution profile. 
 The stability study was carried out in best prepared solid dispersion formulations and 
nanoparticles Glibenclamide. The accelerated stability study was conducted over the 30 days. As 
per results no physical changes takes place at the end of stability studyand there was no 
degradation of drug after storing for 30 days at only 2-3% of drug was degraded after the end 
stability studies. . 
 The dissolution profile of marketed available formulation was compared to the prepared 
best solid dispersion Glibenclamide. The release pattern prepare best solid dispersion 
Glibenclamide can be better than the marketed available formulation. 
Finally it is proven that the solid dispersion by solvent evaporation technique is a promising 
technique to improve dissolution rate of poorly soluble drugs and the technique used for the 
preparation of solid dispersion was simple, cost effective, stable, and easy to scale up. 
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